Podcasts about Cleveland Clinic

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed evolving administration strategies for multiple myeloma therapies, primarily focusing on subcutaneous and on-body administration. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.In the first episode of a 3-part series, Drs Faiman and Ailawadhi outlined the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management. They also highlighted the significance of the July 2026 FDA approval of satuximab-irfc (Sarclisa Escena) for subcutaneous injection for multiple myeloma indications, which includes administration with the CirCLIQ on-body delivery system. 

Pickup vs. delivery has a new competitor when it comes to medical prescriptions.The Cleveland Clinic is taking prescription deliveries to the skies with the help of a drone-delivery company.WIRED has highlighted women in tech at the forefront of a 2026 special issue. Hear about the bright minds in tech who are working to improve diversity at the top of the tech industry.We are talking about outer space possibly being the next destination for Google data centers.It's all coming up on this week's Tech Tuesday.Guests:Lindsey Amerine, chief pharmacy officer, The Cleveland ClinicKatie Drummond, WIRED global editorial directorRussell Holly, director of commerce content, CNET

Pickup vs. delivery has a new competitor when it comes to medical prescriptions.The Cleveland Clinic is taking prescription deliveries to the skies with the help of a drone-delivery company.WIRED has highlighted women in tech at the forefront of a 2026 special issue. Hear about the bright minds in tech who are working to improve diversity at the top of the tech industry.We are talking about outer space possibly being the next destination for Google data centers.It's all coming up on this week's Tech Tuesday.Guests:Lindsey Amerine, chief pharmacy officer, The Cleveland ClinicKatie Drummond, WIRED global editorial directorRussell Holly, director of commerce content, CNET

Luke Carignan runs this one solo and flips the format. No crisis, no warnings. Three healthcare workforce stories that went right, and three things healthcare HR can act on because of them.

DOJ Pediatric Hospital Settlements, AI Infrastructure & St. Louis Bourbon Festival (HOUR 4) Summary: Hour 4 opens with Marc Cox and Kim St. Onge analyzing public statements by Vice President Kamala Harris explaining artificial intelligence algorithms, alongside White House press pool credentialing standards and rotation procedures across major media organizations. Executive Director Will Hild of Consumers' Research joins the show to detail a U.S. Department of Justice settlement agreement with major health systems—including Cleveland Clinic, Texas Children's Hospital, Mount Sinai, NYU Langone, CCMC, and UPMC—to end pediatric transition procedures and fraudulent insurance coding practices. Digital 520 founder Noah Kenney joins the broadcast to evaluate Congressional testimony from OpenAI CEO Sam Altman regarding artificial intelligence safety guardrails, human oversight in high-risk sectors, and energy grid demands driven by data center infrastructure development. The hour concludes with St. Louis Bourbon Society leaders James Thomas and Drew Chostner previewing event logistics, vendor lineups, and VIP tasting tiers for the upcoming 2026 St. Louis Bourbon Festival at the Lemp Mansion complex. For official voter registration resources, ballot measure summaries, and election information, consult the Missouri Secretary of State Elections Division. LISTEN TO 97.1 FM TALK LIVE IN ST LOUIS OR STREAM WORLDWIDE AT 971TALK.COM Hashtags: #971FMTalk #StLouis #STLNews #WillHild #NoahKenney #STLBourbonFestival

Marc Cox and Kim St. Onge host Consumers' Research Executive Director Will Hild to evaluate federal oversight of healthcare institutions. Hild details a U.S. Department of Justice settlement framework involving major health systems—including Cleveland Clinic, Texas Children's Hospital, Mount Sinai Health System, New York University Langone Hospital, Connecticut Children's Medical Center, and UPMC Children's Hospital of Pittsburgh—to end pediatric gender transition procedures and fraudulent insurance billing practices. The discussion examines medical liability frameworks, insurance reimbursement coding, and Congressional committee inquiries into hospital system practices. The interview concludes with an analysis of Missouri ballot initiative proposals regarding pediatric medical regulations. For official voter guidelines, sample ballots, and election information, consult the Missouri Secretary of State Elections Division LISTEN TO 97.1 FM TALK LIVE IN ST LOUIS OR STREAM WORLDWIDE AT 971TALK.COM Hashtags:#971FMTalk #StLouis #STLNews #WillHild #ConsumersResearch #DOJSettlement

The Friday broadcast of The Marc Cox Morning Show hosted by Marc Cox and Kim St. Onge opens with tributes for regional "Dolly Parton Day" (9/25) following her August 25, 2026 passing and legal analysis of pending stay applications before U.S. Supreme Court Justice Brett Kavanaugh regarding Missouri's congressional redistricting map appeal. On the shortlist and Kim on a Whim, the hosts examine speech excerpts from Israeli Prime Minister Benjamin Netanyahu at the United Nations General Assembly, Name, Image, and Likeness (NIL) court filings involving former Saint Louis University center Robbie Avila, and recap attendance following the beatification Mass for Archbishop Fulton J. Sheen at The Dome at America's Center. In local coverage, the St. Louis Morning Brief honors Naismith Basketball Hall of Fame inductee Bob Pettit, who passed away at age 93 after leading the St. Louis Hawks to the 1958 NBA championship, and reviews developer tax referendum petition drives in Ballwin. Financial reporter Nicole Murray delivers market updates on energy commodities and corporate retail, followed by In Other News, sponsored by Zerorez St. Louis, covering Katmai National Park's Fat Bear Week 2026 competition. National security analyst Dr. James Carafano of The Heritage Foundation evaluates diplomatic strategy and UN General Assembly addresses. U.S. Representative Bob Onder (MO-03) provides updates on state election administration guidelines and $45 million in federal rural healthcare funding allocated to Missouri. Consumers' Research Executive Director Will Hild details U.S. Department of Justice settlement agreements with major hospital systems—including Cleveland Clinic and Texas Children's Hospital—ending pediatric gender transition procedures. Digital 520 founder Noah Kenney reviews artificial intelligence guardrails and data center power grid impacts, while St. Louis Bourbon Society organizers James Thomas and Drew Chostner close the show previewing the 2026 St. Louis Bourbon Festival. For official voter registration guidelines, election district lookup tools, and sample ballots, consult the Missouri Secretary of State Elections Division. LISTEN TO 97.1 FM TALK LIVE IN ST LOUIS OR STREAM WORLDWIDE AT 971TALK.COM Hashtags: #971FMTalk #StLouis #STLNews #BobPettit #JimCarafano #BobOnder

Hubert Fernandez, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the TEMPO trials evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as monotherapy in early Parkinson disease and as an adjunct to levodopa in patients with motor fluctuations. He examines efficacy, tolerability, adverse events, and where tavapadon could fit within the evolving Parkinson disease treatment landscape.

Dr. Justin Abbatemarco talks with Dr. Irene Cortese about recent advances in the treatment of progressive multifocal leukoencephalopathy (PML), focusing on immune-based therapies like virus-specific T cells and immune checkpoint inhibitors.  Read the related article in The New England Journal of Medicine.  Disclosures can be found at Neurology.org.  Show transcript:  Dr. José Merino: This is José Merino, editor-in-chief of the Neurology Family of Journals. The Neurology Podcast provides practical information to neurologists and other clinicians to help them provide better care for their patients. Thanks for listening, and have a great week. Dr. Justin Abbatemarco: Hello and welcome. This is Justin Abbatemarco with the Cleveland Clinic here with Irene Cortese to discuss an update on progressive multifocal leukoencephalopathy treatment in light of a New England Journal of Medicine correspondence, Resolution of PML After Treatment with Virus-Specific T Cells and HCT. Irene directs the Experimental Immunotherapeutics Unit at NINDS. Hello and welcome. Dr. Irene Cortese: Hi, thank you for the invitation to join you today. Dr. Justin Abbatemarco: It's a pleasure to have you on and to talk about this expanding space in rare disease. And maybe if we could start off, can we just take an overview on how PML usually presents and why does it remain so difficult to treat? Dr. Irene Cortese: PML, or progressive multifocal leukoencephalopathy, is an opportunistic infection of the brain that is caused by the JC virus. And most of us carry this virus lifelong and without any symptoms, and it really only causes disease when the immune system is significantly compromised and loses the ability to keep it in check. And so when that happens, the virus can gain the ability to infect oligodendrocytes, and this can lead to the rapidly progressive demyelinating infection called PML. These lesions that develop in PML are typically located in the white matter, and they are most often multifocal. And this leads to the clinical manifestation of a combination of cortical and subcortical symptoms that evolve over weeks to months. And, unfortunately, if immune competence can't be restored quickly, then the disease is fatal within just a few months. And so that's really the core of the problem here, is that there is no effective direct antiviral treatment. And the only thing that works is restoring the immune system ability to control it, but that's often very difficult to do. When it's even possible, it's frequently just not even fast enough. And so you can see this even in situations where you'd think that we'd have an advantage, for example, in HIV-associated PML, where we do have effective antiretroviral therapy. Even there, restoring immune competence can sometimes just take too long relative to how quickly PML progresses. And so on top of all that, PML is really quite rare and is also remarkably heterogeneous because it can occur in very different patient populations from HIV to hematological malignancy to genetic immune deficiencies. And this rarity and heterogeneity really make both the diagnosis difficult and also treatment development quite difficult. Dr. Justin Abbatemarco: It's such a interesting story, and these different backgrounds really present different challenges. But at these last few years, this has been a success story in some way because we've seen so much effort and research into this rare disease space, which is encouraging. We mentioned this at the top, but there are immune checkpoint inhibitors that have at least been trialed for this T cell exhaustion to see if we can boost the immune system, and then more recently with your work around allogeneic-specific T cells to help clear the infection. What have you taken away from those updates? Dr. Irene Cortese: The biggest takeaway is that these two approaches, checkpoint inhibitors and Virus-Specific T Cells, have really transformed the way that we think about PML. So for decades, our only option was really to try to reverse the underlying immune suppressive condition and just hope that the immune system caught up in time. And now we have these two active strategies to try to speed this process up. Importantly, both these strategies have validated the same core hypothesis that even without a direct antiviral agent, we can improve PML outcomes by restoring effective antiviral immunity. And that said, each of these approaches has real limitations. So first of all, they don't work in all patients. And we have best estimates of success rates somewhere in the 50 to 60% range overall. With checkpoint inhibitors, the fundamental issue is that you're trying to unleash an immune response that has to already be there in some latent or exhausted form. For example, in patients with very advanced immune compromise where the T-cell compartment is essentially absent, there's just nothing left to invigorate, and so checkpoint blockade is really unlikely to help. And even when they do work, there is a real risk of exacerbating underlying autoimmune disease as well as the risk of leading to immune reconstitution inflammatory syndrome, or IRIS, where inflammation in the central nervous system of this immune system waking up and attacking the infection can actually lead to severe morbidity and even death in some patients. Virus-Specific T Cells have a whole different set of limitations. These are mostly practical and logistical at this point. Access is really the big one because there are only a handful of centers worldwide that can manufacture Virus-Specific T Cells. And so this just isn't something you can easily do everywhere or quickly. And also, biologically, every virus-specific T-cell product which is made from a different donor is essentially a different drug. And so it's really hard to predict how any given cell product will actually behave in a given patient. I should also mention that for both these approaches, they truly are still experimental. We don't have any controlled studies, and so most of what we're working from is really retrospective series and case reports. And we definitely have no head-to-head data. And so while we apply general principles estimating residual immune capacity or weighing the risk of exacerbating immune-mediated adverse events, we're really making individualized judgment calls rather than following an evidence-based algorithm. Dr. Justin Abbatemarco: And could you talk about those Virus-Specific T Cells? It's not something we use commonly in neurology. How do those work? And have they been used in other spaces successfully that we've been able to maybe apply some of those principles here? Dr. Irene Cortese: Yeah. So Virus-Specific T Cells were really first developed in the transplant setting, and they were essentially a way to bridge patients immediately following myeloablation. And in the period of time it took them to fully immune reconstitute a brand new immune system, it was a way to protect them from the common viral infections mostly that can develop in this time period and that led to such high morbidity and even mortality. And so the way this is done is that you basically take healthy lymphocytes from a healthy donor, and you can train them in vitro by ex vivo expansion and stimulation to basically become professional killers of the particular virus of interest so that, at the end of this expansion period, you basically have a enriched antiviral product that can be adoptively transferred to the patient recipient. And they may not last for a very long time, however, they can, especially with repeated infusions, provide the necessary immunity to bridge until definitive immune reconstitution is achieved. And so the initial experience with Virus-Specific T Cells was really against the various viruses that are so common in the post-transplant setting, like CMV, EBV, adenovirus, and also BK virus, which is a cousin, let's say, of the JC virus. And over time, the process for manufacturing Virus-Specific T Cells has become more and more streamlined. And so back as in 2015, 2017, we started to realize that perhaps these types of cell products might even be used to treat an acute infection and not just to administer in the setting of a planned transplant. And so essentially we've done exactly this, basically copied these manufacturing methods from the transplant world to make Virus-Specific T Cells against the JC virus and can then use them to treat PML. I should mention that BK virus is very similar in structure to the JC virus. And for that reason, what we learned early on when we started to apply Virus-Specific T Cells to the treatment of PML was that we could actually use Virus-Specific T Cells that were made against BK virus and successfully treat PML. More recent years, groups have been manufacturing JC virus-specific BST, but those BK Virus-Specific T Cells can still be used to treat PML. Dr. Justin Abbatemarco: That's really incredible. And it's so cool when we borrow things from these other fields to help inform rare diseases within neurology space. Maybe it's a perfect segue into the cases report in New England Journal of Medicine where you had two cases with inborn errors of immunity. You've utilized the strategy and then stem cell transplant. Walk us through those cases. What did you see? What did we learn from these that we can apply more broadly? Dr. Irene Cortese: Our paper really told the story of our experience of treating these two young men. Both of them had developed PML in the setting of an inborn error of immunity. One of them had DOCK8 deficiency, and he also had Sézary syndrome as a comorbid condition. And the second patient had a CD40 ligand deficiency. And for both these patients, we basically adopted the same strategy, which was to first try to gain control of the JC viral infection. And once that infection was actually under control, then we went ahead and proceeded to definitive treatment of their underlying genetic immune deficiency, which was transplant in their setting to correct the real root problem that they had. And what I think was perhaps most instructive in this experience is what happened after transplant in both cases. So transplant obviously involves a period of renewed immune vulnerability, and that's exactly when we feared that the PML might come back, even though we had been able to gain control, at least temporarily, using this adoptive transfer Virus-Specific T Cells. Fortunately, in these two cases, that didn't happen. And in fact, patient one actually developed IRIS shortly after engrafting with worsening neurological symptoms and also imaging that showed active inflammation, which responded well to steroids. And he's now years out with no evidence of PML or his prior malignancy, which was also treated by the transplant. The second patient's course was complicated by cryptogenic organizing pneumonia, or COP, which can happen in the post-transplant setting, and did require steroids. And this did cause a transient uptick in the JC viral copy number in the spinal fluid, but this resolved once the steroids were tapered. And this patient also is now several years out with only mild residual neurological deficits. So it's important that for both these patients, the transplant donors, in addition to undergoing collection for the transplant itself, they also underwent a collection to make extra rescue Virus-Specific T-Cell products that we had on hand just in case the PML relapsed post-transplant, which of course was not, in the end, needed. And so basically, the overall strategy for both these patients was sequential and deliberate. First to establish virus-specific immune control, and only then proceeding to the definitive but higher risk step of transplant with the safety net available in case virus reactivated during that post-transplant period. Dr. Justin Abbatemarco: The complexity of these cases, though, and the successful outcome is just incredible. And again, we don't always treat these level of patients, but most neurologists will see PML during their career. How do you think this helps inform this broader field of PML treatment in your mind? Dr. Irene Cortese: For me, these two cases really crystallized the idea of immune facilitation as a bridge rather than as a standalone endpoint. For example, in these two patients, Virus-Specific T Cells could not have led to a definitive cure because the underlying immune defect was still there, but they could buy time and control the virus long enough to get to something that could actually fix the underlying problem, which in this case was the transplant. And I'll be honest, proceeding to transplant in a patient with active or recent PML was really frightening. And clearly that is not an option or appropriate at all for the majority of patients with PML. So I guess that the broader lesson here is that Virus-Specific T Cells or potentially other immune-facilitating strategies might serve as a bridge to get us to the point where we either have a way to address that root cause of immune suppression or just buy us the time needed to recover from immune suppressive exposures and perhaps opens up the question of how we might use sequential strategies and combinations of strategies to optimize the care of these patients. Dr. Justin Abbatemarco: Really appreciate your paradigm of how you think about these cases in treatment, and yet you can have these short-term strategies to bridge patients to have an improved immune response to get this under control. Could we talk about other common examples? So we have natalizumab-induced PML cases, HIV-associated PML cases. How would you think about managing those, so outside of these inborn errors of immunity? Dr. Irene Cortese: Each PML patient is somewhat unique, and definitely the underlying condition that is driving the immune suppressed state is really critical in mapping out what we need to do. I think of HIV-associated PML or even natalizumab-related PML as being somewhat unique. Because unlike most other causes of PML, we actually do have clear and reliable ways to restore immune competence, so basically antiretroviral therapy in HIV infection or simply discontinuing the non-immune-depleting drug natalizumab in the case of natalizumab-related PML. And so this is obviously a real advantage compared to many of the other underlying conditions where there really is no good way to reverse that immune suppression at all. That said, in some patients, for example, with advanced AIDS and very low CD4 counts, immune reconstitution can still be very slow even when the HIV replication itself is well controlled. And so in a subset of patients, the PML can still really pace the recovery. And so we do sometimes need strategies to bridge that gap. And basically. we would consider the same immune restoration approaches that we've been talking about right now. There is an added layer of complexity here that's a bit more, let's say, unique to HIV-related PML or to the setting of natalizumab-related PML, which is that in both these cases, immune reconstitution is going to happen eventually. And when it does, then many of those patients do experience PML IRIS where the constituting immune response paradoxically worsens the neurological injury by attacking the infected tissue. And so this really needs to be watched for and managed typically with steroids. And certainly this risk of developing PML IRIS needs to be really considered if we are going to use strategies to boost or facilitate immune reconstitution in the setting of HIV infection or natalizumab-related PML. And we just have to be particularly mindful because there's already a very high likelihood of developing PML IRIS independently of getting that extra boost. Comparatively, in the setting of non-HIV-related PML or not in the setting of natilizumab treatment, I think that strategies like checkpoint inhibition and Virus-Specific T Cells have really been game-changing because, historically, these patients had no equivalent to antiretroviral therapy with no reliable path to reconstituting immunity. And we're really hoping that these approaches will start to bring the outcomes that we've seen, for example, among HIV-related PML and in the setting of natalizumab and PML to these other underlying conditions and achieve the same immune control and survival rates that are achieved in at least a substantial portion of these patients. Dr. Justin Abbatemarco: It's been so exciting. Again, the updates in this field when we really did... We had nothing to offer patients for so long and now to have conversations that are a little bit different. Can I ask you to peer around the corner? What does the future look like in your mind? Do you see other therapies that are potentially at play and maybe right now are there clinical trials that we could enroll patients so that we can help inform the field more broadly? Dr. Irene Cortese: Yeah. So I think that ways to facilitate and accelerate immune reconstitution have clearly been shown to be a valid strategy. And so what I expect and hope is that in the years to come, we'll learn to harness that better and learn to identify which patients are most likely to respond to particular types of strategies to facilitate immune reconstitution. It's really important, I would say, that patients participate in trials because the field really does lack controlled data and it lacks head-to-head comparisons. And so every patient enrolled in a trial or a well-structured registry is really contributing to how the next patient gets treated. And given just how rare and heterogeneous PML is, we're just not going to advance this field through isolated case reports alone. And so we really do need patients and their physicians to be willing to participate in structured and collaborative research. The Holy Grail is, of course, a direct antiviral agent that would really broaden our ability to treat patients and potentially also continue to treat whatever that underlying condition was that led them to the risk of PML in the first place, so, for example, patients receiving treatment for cancer or patients having an autoimmune disease that requires immune suppression. And so I am hopeful that eventually the direct antiviral will be identified. And along that line, what I can mention is there are certainly clinical trials that are ongoing. At NIH, we have an active natural history study from where we can funnel patients into various experimental treatment strategies, including Virus-Specific T Cells or checkpoint inhibitors. Or right now, we actually do have an ongoing trial of intravenous brincidofovir as a possible direct antiviral strategy. What I hope for the future is that we will find ways to really collaborate and to form national as well as international consortia so that we can accelerate the development of these treatments. Dr. Justin Abbatemarco: We have things we can do now, and then we can help inform care for our future patients as well. So these are great messages, and I can't thank you enough for coming on. Again, most of these developments have been under your guidance, and we appreciate your leadership in this space and helping to give us this insight into this really rare disease. For folks, they can check out the article. It's in the New England Journal of Medicine, Resolution of TML After Treatment with Virus-Specific T Cells and HCT. Irene, thank you for coming on. Dr. Irene Cortese: Thank you so much. Dr. Stacey Clardy: This is Stacey Clardy, your podcast editor. If you've enjoyed the podcast, please take a few moments to subscribe, rate, and review the Neurology Podcast through Apple Podcasts, Google Podcasts, Spotify, or wherever you listen. And remember, you can always head to neurology.orgpodcast for our full list of past episodes, or you can also search by keyword on your podcast app for any neurology-specific topics.

Divorce can bring anxiety, self-doubt, and beliefs about ourselves that we may not even realize we are carrying. Sometimes those beliefs have been with us for decades, quietly influencing what we think we can handle, what we expect from ourselves, and even what we believe our life is supposed to look like.Today, Strategic Divorce Consultant Mardi Winder welcomes back Performance and Mindset Expert Karen Ross for a fascinating conversation about hypnotherapy, guided visualization, and the power of our subconscious beliefs.Karen explains what hypnotherapy actually looks like and clears up some of the misconceptions created by stage hypnosis. Mardi and Karen also discuss how guided visualization can help people become more aware of limiting beliefs and begin creating a different picture of what they want moving forward.For someone navigating divorce, these techniques may be particularly useful when dealing with anxiety surrounding mediation, difficult communication, or beliefs such as “I can't handle this on my own” or “my life was supposed to look different.” Rather than remaining focused entirely on the problem, Karen encourages clients to begin asking a different question: How do I want this to be?Q&AQ: What does hypnotherapy actually feel like?A: You aren't asleep or unaware of what's happening. Karen and Mardi describe it as a deeply relaxed state that can feel similar to guided meditation, except the experience is personalized around your specific goals. You remain conscious and aware throughout the process.Q: Can a hypnotherapist make you do something you don't want to do?A: No. Hypnotherapy isn't mind control, and the suggestions used in a session are based on what the client wants to accomplish. Mardi and Karen explain that the process isn't about overriding someone's values or beliefs. It is designed to help the client work toward changes they have chosen for themselves.Q: How could hypnotherapy be helpful during divorce?A: Divorce can create considerable anxiety and can also bring long-standing limiting beliefs to the surface. Mardi shares how she uses hypnotherapy with clients preparing for mediation to help them relax, reduce anxiety, and visualize themselves moving through the experience in a more positive way. It can also be used after divorce when someone is working through beliefs about what their life “should” look like.Q: What if a positive statement doesn't feel believable to you?A: Karen suggests starting with willingness. Instead of forcing yourself to say something you don't believe, you might begin with “I'm willing to...” and move toward the change. Mardi shares another approach: “There's a part of me that knows I can...” Both can create room for a new possibility without requiring you to pretend you already believe something you don't.Q: Is hypnotherapy usually a one-session process?A: Not necessarily. Both Karen and Mardi discuss the value of repetition and reinforcement. Karen combines solution-focused coaching with hypnotherapy and typically begins by helping clients identify what they want to be different. The hypnotherapy can then reinforce that new vision, while clients also learn techniques they can use on their own.About the Guest:Karen Ross is a Performance Mindset Expert who uses dynamic guided visualization, solution-focused coaching and hypnotherapy to help clients break through mental barriers so they perform at a higher level. While she has a strong niche with athletes of all ages, executives, entrepreneurs and other high-achievers also overcome anxiety, sharpen focus, strengthen confidence, and unlock peak performance in both life and business. Her diverse background, from executive search to interviewing renowned thought leaders on a former Chicago radio show, has sharpened her ability to quickly connect with people and uncover what truly drives their success. This work can include hypnosis and many are surprised to learn that the practice of hypnosis has been used by icons like Michael Jordan, Tiger Woods, Albert Einstein, and is now used at renowned institutions like Mayo Clinic and Cleveland Clinic. When used as a therapeutic process, it can be life-changing.For Karen's gift: https://karenrossnow.com/ To connect with Karen:LinkedIn: https://www.linkedin.com/in/karenrossnow/ Website: https://karenrossnow.com/ Email: info@karenrossnow.comAbout the HostMardi Winder is a Strategic Divorce Consultant and High-Conflict Divorce Coach who helps high-achieving individuals navigate divorce with clarity, confidence, and control. Drawing on more than 30 years of experience in mediation, divorce coaching and conflict resolution, she supports clients in making smart decisions while reducing emotional and financial fallout, particularly in high-conflict, high-asset and complex divorces. Mardi is the founder of Positive Communication Systems, LLC, and the Strategic Divorce Directory, LLC.For Mardi's gift: The Resilience Building Blueprint: A 28-Day Journey To A Stronger You https://www.divorcecoach4women.com/rbbConnect with Mardi on Social Media:Facebook - https://www.facebook.com/Divorcecoach4womenLinkedIn: https://www.linkedin.com/in/mardiwinder/Instagram: https://www.instagram.com/divorcecoach4women/YouTube: https://www.youtube.com/@divorcecoach4womenThanks for Listening!Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page.Do you have feedback or questions about this episode? Leave a comment in the section below!Subscribe to the PodcastIf you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts. You can also subscribe in your favorite podcast app.Leave an Apple Podcast ReviewRatings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.

Federal indictment filed against Columbus man related to the death of an Indiana teen; workers at Cleveland Clinic's Lutheran Hospital are on strike; owner of a Toledo motel injured in an assault; republican senators Husted and Moreno introduce legislation that would withhold federal highway funding from states that issue driver's licenses to undocumented immigrants.

Federal indictment filed against Columbus man related to the death of an Indiana teen; workers at Cleveland Clinic's Lutheran Hospital are on strike; owner of a Toledo motel injured in an assault; republican senators Husted and Moreno introduce legislation that would withhold federal highway funding from states that issue driver's licenses to undocumented immigrants.

Why are we obsessed with glass skin, poreless complexions and perfectly smooth faces?In this bonus episode, we explore the rise of the K-beauty glass skin trend, our centuries-old obsession with flawless complexions, the war against pores and skin texture, and the growing skincare obsession among children.Because glass doesn't have lines, texture or pores...but glass isn't alive.Are.You.Ready?****************SOURCES & FURTHER READING:American Academy of Dermatology Association. "A Dermatologist's Guide to Skincare From Growing Up to Glowing Up." 2025.American Academy of Dermatology Association. "What Can Treat Large Facial Pores?"Bolen, Rebecca, Tionna Szymanski, Jordanne Nichols, and Kayd J. Pulsipher. "Dermatological Safety of Cosmetic Products Marketed to Children: Insights on the Sephora Kids Phenomenon." Journal of Drugs in Dermatology, Vol. 24, No. 9, 2025, pp. 949-951.Cleveland Clinic. "Sebaceous Filaments: Difference From Blackheads & Treatment." 2023.eSafety Commissioner, Australian Government. "Social Media Age Restrictions."Grist, Kerry. "Dangerous Beauty: Hazardous Chemicals and Poisons in Historic Cosmetics." Science Museum Group, 2022.Hales, Molly, Sarah Rigali, Amy Paller, Walter Liszewski, and Tara Lagu. "Pediatric Skin Care Regimens on TikTok." Pediatrics, Vol. 156, No. 1, 2025, e2024070309.Matts, Paul J., Bernhard Fink, Karl Grammer, and Maria Burquest. "Color Homogeneity and Visual Perception of Age, Health, and Attractiveness of Female Facial Skin." Journal of the American Academy of Dermatology, Vol. 57, No. 6, 2007, pp. 977-984.National Museum of American History, Smithsonian Institution. "Dr. James P. Campbell's Safe Arsenic Complexion Wafers."Reuters. "France's Top Court Blocks Social Media Ban for Under-15s." August 14, 2026.Schallon, Lindsay. "This Woman's 'Glass Skin' Skin-Care Routine Is Going Viral." Allure, 2017.****************Leave Us a 5* Rating, it helps the show!Apple Podcast:https://podcasts.apple.com/us/podcast/beauty-unlocked-the-podcast/id1522636282Spotify Podcast:https://open.spotify.com/show/37MLxC8eRob1D0ZcgcCorA****************Follow Us on Social Media & Subscribe to our YouTube Channel!TikTok:tiktok.com/@beautyunlockedthepodYouTube:@beautyunlockedspodcasthour****************INTRO/OUTRO MUSIC:FASION/ '1-800-DIRTY'/Courtesy of Epidemic Sound

For the 122nd episode of the CIO podcast hosted by Healthcare IT Today, we are joined by Saad Chaudhry, CEO at Evergreen Healthcare Partners, and former CIO, to talk about the roles of C-suite executives! We kick this episode off by discussing what went into Chaudhry’s decision to move from being an IT leader at a provider organization to now being the CEO at Evergreen. Next, we debate why we think more CIOs don’t become CEOs. Then, Chaudhry shares how what keeps him up at night has changed as he transitioned from a CDIO of a large health system to a CEO of a commercial business. We then use this transition to our advantage. CIOs often say they’re the business leaders who happen to lead tech. Since Chaudhry has gone from the outside perspective to being the subject of that belief, we dig into whether or not he still believes that to be true. Next, we talk about what Chaudhry was hesitant to say when he was a CIO that he’s willing to share more openly now. Then, we take a look at the recent Epic UGM to get Chaudhry’s and Evergreen’s reactions. We also discuss the challenges CIOs face and how they should be managing them. Next, we dig into where Chaudhry thinks CIOs should be investing in managed services and when it makes sense to keep things in-house. Lastly, we wrap this episode up with Chaudhry giving his advice to CIOs today. Here’s a look at the questions and topics (inspired by the suggestions of Sarah Hatchett, CIO at Cleveland Clinic, and Shakeeb Akhter, CDO at Memorial Sloan Kettering) we discuss in this episode: What went into your decision to move from being an IT leader at a provider organization to now being CEO at Evergreen? Why do more CIOs not become CEOs? How has what keeps you up at night changed as you transition from a CDIO of a large health system to a CEO of a commercial business? CIOs often say they’re business leaders who happen to lead tech. Now that you’re actually running a business, do you still believe that? What’s something you were maybe hesitant to say when you were CIO that you’re willing to share more openly now? What’s your and Evergreen’s reaction coming out of the recent Epic UGM? What are the challenges CIOs face, and how should they be managing them? Where do you think CIOs should be investing in managed services, and when does it make sense to keep things in-house? What advice would you give to a CIO today? Now, without further ado, we’re excited to share with you the next episode of the CIO Podcast by Healthcare IT Today. We release a new CIO Podcast every ~2 weeks. You can also subscribe to the Healthcare IT Today podcast on any of the following platforms: NOTE: We’ll be updating the links below as the various podcasting platforms approve the new podcast.  Check back soon to be able to subscribe on your favorite podcast application. Apple Podcasts Google Podcasts Stitcher Podcast Radio TuneIn Spotify iHeartRadio Amazon Music Thanks for listening to the CIO Podcast on Healthcare IT Today and if you enjoy the content we’re sharing, please rate the podcast on your favorite podcasting platform. Along with the popular podcasting platforms above, you can Subscribe to Healthcare IT Today on YouTube.  Plus, all of the audio and video versions will be made available to stream on HealthcareITToday.com. We’d love to hear what you think of the podcast and if there are other healthcare CIO you’d like to see us have on the program. Feel free to share your thoughts and perspectives in the comments of this post with @techguy on Twitter, or privately on our Contact Us page. We appreciate you listening! Listen to the Latest Episodes

What if clinical trials could evaluate multiple treatment approaches at the same time and adapt as evidence emerges? In this episode of the ECTRIMS Podcast, host Brett Drummond speaks with Prof. Jeremy Chataway of University College London and Prof. Daniel Ontaneda of Cleveland Clinic about multi-arm, multi-stage clinical trials and their potential to make MS research more efficient and responsive. The episode comes at an especially timely moment. This week, interim results from the OCTOPUS trial showed that alpha-lipoic acid will progress to the next stage of the trial, while the metformin arm will be stopped. These results provide an early demonstration of the adaptive approach discussed in this episode — although the conversation itself was recorded before the interim results were available. Together, they discuss: How multi-arm, multi-stage trials differ from traditional clinical trial designs Why these approaches could be particularly valuable in progressive multiple sclerosis How a single trial framework can allow promising treatments to advance while less promising approaches are stopped The potential benefits for recruitment, participant experience and reducing the time between trial phases The statistical and practical challenges involved in designing and running these complex studies How interim outcomes, imaging and biomarkers could help identify promising treatments earlier What the OCTOPUS trial is investigating — and how its design is being used to evaluate potential treatments for progressive MS Whether the same approach could be used to accelerate the development of remyelination and repair therapies As the first OCTOPUS interim results now show, the adaptive design discussed in this episode is not simply theoretical. This episode offers a particularly relevant look at the thinking behind the trial and the methodology being used to determine which treatments should move forward and which should not. This podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases, Bristol Myers Squibb, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

Dr. Michael Roizen returns for Part 2 of the conversation on longevity, healthspan, and the future of healthy aging. Building on the previous discussion, he dives deeper into The Great Age Reboot and the emerging science behind extending not just lifespan, but years of health, mobility, and vitality. From brain health and stress management to nutrition, movement, purpose, and the latest advances in longevity research, Dr. Roizen shares practical steps people can take today while exploring what the future of medicine may make possible tomorrow.  Key Takeaways:   Healthy aging is shaped by the daily choices we make long before we reach older age.  Brain health benefits from movement, cognitive challenges, stress management, and meaningful engagement.  Nutrition, physical activity, and healthy metabolic markers are important foundations for longevity.  Purpose, friendship, and play can help support a healthier and more fulfilling life as we age.  Emerging advances in gene editing, stem cell research, and other longevity therapies could reshape how we approach aging in the future.   We couldn't highlight incredible stories like this without the support of our sponsor, CommunityAmerica Credit Union. Thank you for helping us promote connection, well-being, and stronger communities. If you're looking for trusted financial wellbeing resources, we invite you to connect with their team and take the next step toward greater financial confidence.  About Dr. Michael Roizen:   Dr. Roizen served as Cleveland Clinic's first Chief Wellness Officer from 2007 to 2019 & founding Chair of its Wellness Institute. The Clinic's Wellness Programs helped the clinic not spend over 1.250 billion dollars for its 101,000 employees & dependents over 11 years compared with national averages and help over 43.6% of participants achieve 6 normals+2 ® for health. This reduced their rate of aging and time of disability equivalent to 12.5 years over an 80 year lifespan.    Dr Roizen is a recipient of an Emmy, an Elle, the Paul Rogers best medical communicator award from the National Library of Medicine, & the Bennett Family Award from GlobalWellnesSummit. He initiated & developed the RealAge concept to motivate behavior change. That started the concept that 60 could be the new 40. He believes that soon 90 will be the new 40—how you can prepare for it is described in his recently released book and app-newsletter, The Great Age Reboot and 4 YOUngevity.com Ai coaching program & free newsletter.    He has authored over 195 peer reviewed scientific publications (he really is a science nerd), four New York Times #1 best sellers, 9 overall top 10 bestsellers including his initial #1 Bestseller in 5 countries, "RealAge: Are You As Young As You Can Be?", "AgeProof—Living Longer without breaking a hip or running out of money" and his book that displaced Harry Potter from #1 on Amazon for 177 days, YOU: On A Diet, The Owner's Manual for Waist Management. He served 16 years on FDA advisory committees, including chairing one for two years. His books have been translated into 44 languages and been number 1 in 5 countries in addition to the USA. He helped start 14 companies including his current Therapeutic Plasma Exchange Company, Lifespan-Edge.com, , co-invented a drug approved by the FDA, co-invented the Cloud (US Patent # 2004/0205055A1 ; his coinventor –who took it from him—was just awarded 673 million dollars from Amazon)and has a weekly podcast now in its 1268th+ week; he and Dr Oz coauthored a daily column syndicated to over 68 newspapers that translates current scientific reports into actionable steps for lay audiences. When Dr Oz declared his candidacy for public office, Dr Roizen has continued the column alone, but have recently started writing it together again, but he has restarted alone as Dr Oz is now USA's CMS Director-Administrator.    He is a recipient of The United Way of Cleveland Humanitarian of the Year Award. He has won over 75 trophies in class A squash competition. His wife is a developmental pediatrician also listed in the Best Doctors in America. The Roizens have two children: Jenny, a PhD organic chemist working for the US Energy Department, and Jeffrey, an MD/PhD faculty member in pediatric endocrinology at Children's Hospital of Philadelphia. Dr. Roizen is devoted to helping people live younger. He consults with patients in Cleveland Clinic's Executive Health and Wellness Programs. He teaches them the 80% likelihood that they can be 40 at calendar age 90, and how to prepare for that.   Connect with Dr. Michael Roizen at:   https://4youngevity.com/    https://lifespan-edge.com/   https://michaelfroizenmd.substack.com/   Connect with Dr. Michelle and Bayleigh at:  https://smallchangesbigshifts.com  hello@smallchangesbigshifts.com  https://www.linkedin.com/company/smallchangesbigshifts  https://www.facebook.com/SmallChangesBigShifts  https://www.instagram.com/smallchangesbigshiftsco  https://www.youtube.com/@smallchangesbigshiftsco    Thanks for listening!  Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page.  Do you have some feedback or questions about this episode? Leave a comment in the section below!  Subscribe to the podcast  If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can also subscribe in your favorite podcast app.  Leave us an Apple Podcasts review  Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts. 

At the recent Midwest Glaucoma Symposium at the Cleveland Clinic, I learned so much from a presentation by Dr Matthew Brink about the benefits of phaco in glaucoma patients. He has some very keen insights and he made the point that it deserves further research and that his findings would benefit from further inquiry. This is the mark of a true expert because the more we know, the more we realize how much more there is to know. This podcast covers that topic but also the rewards and challenges of building his new private practice and the strive to get every patient his best. Very inspiring and truly a future leader in our field, so it's great to enjoy interacting with him at this earlier stage.We feature a new podcast every week on Sundays and they are uploaded to all major podcast services. The full video of the podcast is here on CataractCoach as well as on our YouTube channel. Starting now we have sponsorship opportunities available for the top podcast in all of ophthalmology. Please contact us to inquire.

According to UK charity The Men's Health Forum, two thirds of all men are affected by male pattern baldness in their lifetime. That won't be a surprise to anyone, but would you have guessed that an estimated 50% of women also experience noticeable hair loss according to the Cleveland Clinic. We actually have around 100,000 hair follicles on our head, of which we lose between 50 and 100 every day, completely naturally. Hair loss isn't usually any cause for real concern on its own, but of course it can be caused by cancer treatment. Even if a person's health isn't affected by their hair loss, It can still be an upsetting experience. Some types of hair loss are temporary. This can happen when a person has an iron deficiency, is stressed or loses weight suddenly due to a restrictive diet for example. Isn't hair loss mostly hereditary? Are there any ways of stopping it? What about hair transplants? In under 3 minutes, we answer your questions! To listen to the last episodes, you can click here: ⁠⁠How much do surrogate mothers get paid?⁠⁠ ⁠⁠What is the Barnum effect?⁠⁠ ⁠⁠How to spot, prevent and treat heatstroke ?⁠⁠ A podcast written and realised by Joseph Chance. First broadcast: 24/2/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. The following question refers to Section 4.3 of the 2025 ACS Guidelines. The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Cleveland Clinic interventional and structural cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Eunice Dugan, and then by expert faculty Dr. Binita Shah. Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee. Question #5 A 64-year-old woman with NSTE-ACS is taken to the cardiac catheterization laboratory. She is P2Y12 inhibitor-naive as she was unable to tolerate oral intake due to severe nausea and vomiting. Coronary angiography reveals a high-grade, thrombotic lesion in the mid-Right Coronary Artery. The interventionalist decides to initiate an intravenous P2Y12 inhibitor before proceeding with PCI. Which of the following is the most appropriate management strategy? A Administer Cangrelor as a 30 mcg/kg IV bolus followed by a 4 mcg/kg/min infusion for at least 2 hours or the duration of PCI, whichever is longer. B Administer Eptifibatide (GP IIb/IIIa inhibitor) as a routine double-bolus followed by an infusion to replace the need for P2Y12 inhibition. C Delay the procedure for 2 hours to allow for the administration and absorption of 600 mg of oral Clopidogrel. D Administer Cangrelor as a 180 mcg/kg bolus followed by a 2 mcg/kg/min infusion for exactly 1 hour. Answer #5 Explanation The correct answer is A.  Cangrelor is the only intravenous P2Y12 inhibitor currently available. It is a direct-acting, intravenous antagonist of the P2Y12 receptor characterized by rapid and potent platelet inhibitory effects, with restoration of platelet function occurring within 1 hour of drug discontinuation. It also has a very short half-life (3–6 minutes). Among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor, intravenous cangrelor may be reasonable to reduce periprocedural ischemic events (Class 2B; LOE B-R). Dosing Strategy: Bolus: 30mcg/kg IV bolus administered rapidly (under 1 minute) before PCI begins. Infusion: 4 mcg/kg/min IV infusion. Duration: The infusion must run for at least 2 hours or for the duration of the PCI, whichever is longer. Transition to Oral Therapy: Ticagrelor: 180mg can be given at any time (during or after the infusion). Prasugrel/Clopidogrel: loading dose must be given immediately after the infusion is stopped. Giving these earlier can lead to a drug-drug interaction where the Cangrelor prevents the active metabolite from binding to the receptor. In the CHAMPION PHOENIX trial, cangrelor was studied versus clopidogrel in patients undergoing PCI for acute or stable coronary syndromes. Cangrelor was administered as an intravenous bolus prior to PCI followed by an infusion for at least 2 hours or for the duration of the procedure, whichever was longer. In the control arm, clopidogrel was administered as a 600- or 300-mg loading dose immediately before or after PCI. At 48 hours, the primary endpoint of all- cause death, MI, ischemia-driven revascularization, or stent thrombosis was significantly reduced with cangrelor, with similar effects observed among those presenting with NSTE-ACS or STEMI. Glycoprotein IIb/IIIa receptor inhibitors are parenterally administered drugs that block platelet aggregation by preventing platelet cross-linking via fibrinogen or von Willebrand factor binding to the glycoprotein IIb/IIIa receptor. Routine administration of GP IIb/IIIa inhibitors before PCI is not recommended and is associated with increased bleeding without improving ischemic outcomes. (Class 3 – No Benefit). In current practice, the role of glycoprotein IIb/IIIa receptor inhibitors is largely limited to adjunctive use at the time of PCI in patients with large thrombus burden or as “rescue” or “bailout” therapy in patients with PCI complications such as no-reflow or persistent or recurring thrombus at the lesion. B is incorrect. Routine “upstream” or periprocedural use of GP IIb/IIIa inhibitors (GPI) is Class 3 (No Benefit) for most patients. Large trials (like EARLY-ACS) showed that routine GPI use significantly increases major bleeding without a proportional decrease in ischemic events compared to modern P2Y12 inhibitors.  C is incorrect. In patients with NSTE-ACS or STEMI who are already in the lab, delaying the procedure to wait for oral drug absorption is not recommended.  D is incorrect. The correct bolus is 30mcg/kg. Cangrelor must be infused for at least 2 hours or the duration of the PCI, whichever is longer. Stopping at 1 hour would leave a “gap” in platelet inhibition before an oral agent can take effect. Because Cangrelor’s half-life is only 3–6 minutes, a premature stop increases the risk of acute stent thrombosis. Main Takeaway Cangrelor may be reasonable among patients with ACS undergoing PCI who have not received a P2Y12 inhibitor to reduce periprocedural ischemic events (Class 2b, LOE B-R). Guideline Loc. Section 4.3.3-4.3.4

This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.  The following question refers to Section 3.2 of the 2025 ACS Guidelines. The question is asked by Thomas Jefferson medical student and CardioNerds Academy Intern Dr. Grace Qiu, answered first by Cleveland Clinic interventional and structural cardiology fellow and member of the CardioNerds Interventional Cardiology Council Dr. Eunice Dugan, and then by expert faculty Dr. Binita Shah. Dr. Binita Shah is an associate professor of medicine, interventional cardiologist, Director for research in Interventional Cardiology, and Director of the Department of Medicine Clinical Investigator Track at NYU. She is also an associate director of interventional cardiology and director of the transcatheter valve program at the VA New York Harbor Healthcare System. She was a member of the 2025 ACS Guidelines writing committee. Question #3 A 55-year-old woman is brought to the Emergency Department after an out-of-hospital cardiac arrest. She had a witnessed collapse with an initial shockable rhythm. Return of Spontaneous Circulation (ROSC) was achieved after 15 minutes of Advanced Cardiac Life Support (ACLS). Her post-resuscitation ECG shows diffuse ST-segment depression but no ST-segment elevation. She remains comatose. Which of the following is the most appropriate next step in her management regarding coronary angiography? A Immediate emergency coronary angiography (within 2 hours) should be performed. B Routine emergency coronary angiography is not recommended in the absence of ST-segment elevation or hemodynamic instability. C Coronary angiography should be delayed for at least 72 hours to allow for neurological recovery. D Fibrinolytic therapy should be administered immediately if the patient cannot reach a cath lab within 90 minutes. Answer #3 Explanation The correct answer is B. In resuscitated patients who are comatose after cardiac arrest, electrically and hemodynamically stable, and without evidence of STEMI, immediate angiography is not recommended due to lack of benefit (Class 3: No Benefit; LOE A) Patients who have been resuscitated after cardiac arrest and are noncomatose or who are comatose with favorable prognostic features and with evidence of STEMI, should undergo PPCI to improve survival. (Class 1; LOE B-NR). For patients such as this one, a delayed or selective approach should be taken once the patient is stabilized. Early angiography should not be denied solely based on a comatose state, but it should be deferred if there are clear non-cardiac causes for the arrest or if the patient’s overall prognosis is futile. A is incorrect because recent evidence shows no benefit to “emergency” PPCI for stable patients without ST-elevation. C is incorrect because while we wait for stability, we don’t necessarily have a fixed 72-hour “mandatory” delay for the heart if ischemia is suspected. D is incorrect, as fibrinolysis is generally not indicated for post-arrest patients without clear STEMI and carries risks in a post-CPR setting due to potential trauma. The MIRACLE2 Score is a tool for neuroprognostication. It helps clinicians estimate the likelihood of a poor neurological outcome at 6 months. A high score suggests that the benefit of an invasive procedure may be outweighed by the severity of the brain injury. Components of MIRACLE2: M – Missed (unwitnessed) arrest I – Initial non-shockable rhythm R – Reactive pupils at ROSC A – Age (points increase significantly at >60 and >80) C – Rhythm change (e.g., VF to PEA) L – Low pH (pH < 7.20) E – Epinephrine (any dose given) Clinical Threshold: A score of >5 indicates a high risk of poor neurological recovery, which may lead a Heart Team to favor stabilization over immediate emergency angiography in patients without ST-elevation. Early recognition of STEMI in resuscitated patients and direct transfer to a PCI-capable center is associated with improved survival. Survival-to-hospital discharge in the patient who is comatose with out-of-hospital cardiac arrest is

You matched into your dream program... but only after submitting 80 applications, spending thousands of dollars, and losing sleep wondering if anyone was even reading yours. Meanwhile, on the other side of the screen, a program director is staring down a thousand applications for six spots, trying to figure out who's actually serious about coming. Sound familiar? Join Mckenzie Roebuck, Milanie Milan, Sarah Lund, and Bryanna Stukes of CoSEF as they unpack the residency application arms race: why uncertainty drives overapplication, what preference signaling and application caps actually solve, the trade-offs of virtual versus in-person interviews, and how better transparency, advising, holistic review, and even AI might help applicants and programs find the right fit. Hosts: Dr. Mckenzie Roebuck, CoSEF BTK Lead, Inova Fairfax Medical Campus, mckenzie.rowe@inova.org, insta @mrowemd, X @mrowemd1  Dr. Milanie Milan, Cleveland Clinic, milanie.milan98@gmail.com, insta @m.mdgram Dr. Sarah Lund, Mayo Clinic, slund@alum.mit.edu, X @DrSarahLund Dr. Bryanna Stukes, UT Southwestern bryanna.stukes@UTSouthwestern.edu CoSEF: X @surgedfellows, cosef.org Learning objectives: Explain how uncertainty across the residency selection process drives overapplication and distinguish the Match algorithm from the broader application ecosystem Describe how preference signaling, application caps, and interview format affect applicant and program behavior, including equity trade-offs Identify ways programs can improve both competitiveness and program-level transparency Discuss how investment in holistic review and mission-specific selection criteria may improve application review while introducing new challenges.  References: House Committee on the Judiciary. Medical Mis-Match: How a Residency Hiring Monopoly Harms Patients, Doctors, and the American Public. Published online March 27, 2026. National Resident Matching Program. Advance Data Tables: 2026 Main Residency Match. NRMP. Published March 20, 2026. Accessed August 2026. https://www.nrmp.org/match-data/2026/03/advance-data-tables-2026-main-residency-match/. Ulin L, Bernstein SA, Nunes JC, et al. Improving Transparency in the Residency Application Process: Survey Study. JMIR Form Res. 2023;7:e45919. doi:10.2196/45919PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38145482/ American Medical Association. Transparency in the Resident Physician Application Process (Issue Brief). Published online November 2023. Accessed August 2026.https://www.ama-assn.org/system/files/cme-issue-brief-resident-application-process.pdf. Nilsen K, Walling A, Callaway P, et al. "The End Game" — Students' Perspectives of the National Residency Matching Program: A Focus Group Study. Med Sci Educ. 2018;28(4):729-737. doi:10.1007/s40670-018-0627-1PubMed Link: https://pubmed.ncbi.nlm.nih.gov/34646549/ Weissbart SJ, Kim SJ, Feinn RS, Stock JA. Relationship Between the Number of Residency Applications and the Yearly Match Rate: Time to Start Thinking About an Application Limit? J Grad Med Educ. 2015;7(1):81-85. doi:10.4300/jgme-d-14-00270.1PubMed Link: https://pubmed.ncbi.nlm.nih.gov/26217439/ Angus SV, Williams CM, Kwan B, et al. Drivers of Application Inflation: A National Survey of Internal Medicine Residents. Am J Med. 2018. doi:10.1016/j.amjmed.2018.01.002PubMed Link: https://pubmed.ncbi.nlm.nih.gov/29355512/ Lund S, Santucci NM, Zarate Rodriguez J, et al. Message Received? Applicant Insights on Preference Signals in General Surgery Residency Recruitment. J Surg Educ. 2026;83(9):104096. doi:10.1016/j.jsurg.2026.104096PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42418854/ Woodward JM, Gan CY, Foote DC, et al. Thanks for the Signal—Now What? Program Director Perspectives on How Preference Signals Are Shaping General Surgery Residency Recruitment. J Surg Educ. 2026;83(9):104061. doi:10.1016/j.jsurg.2026.104061PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42418853/ Mullens CL, Picart JK, Dualeh SHA, et al. A Practical Approach for Implementing Holistic Review for General Surgery Resident Recruitment. J Surg Educ. 2026;83(9):104069. doi:10.1016/j.jsurg.2026.104069PubMed Link: https://pubmed.ncbi.nlm.nih.gov/42436210/ Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium: https://behindtheknife.org/premiumOral Board Review: https://behindtheknife.org/oral-boardOral Board Simulator: https://behindtheknife.org/oral-board/simulatorGeneral Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-reviewOBGYN Oral Board Review Course: https://behindtheknife.org/course/obgyn-oral-board-reviewSurgical Critical Care Review: https://behindtheknife.org/premium/surgical-critical-care-reviewEPA Playbook: https://behindtheknife.org/course/epa-playbookSurgical Instrument Flashcards: https://behindtheknife.org/course/surgical-instrument-flashcardsABSITE Review: https://behindtheknife.org/course/absite-2026-exam-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Histamine is quite possibly the most popular buzzword in healthcare right now and for good reason. For those living with a vestibular condition and dealing with a histamine intolerance, it can feel like a lot to understand and manage. In this episode, I’m breaking down what histamine is, what histamine intolerance can look like, how it’s impacting vestibular disorders and migraine, and what you can do about it. In this episode, we'll dig into: What histamine is and its role in your immune system, digestion, sleep, mood, memory, and more The 4 types of histamine receptors and what they have to do with your symptoms Histamine intolerance vs. MCAS What happens when you don’t have enough of the DAO enzyme What contributes to histamine intolerance and what it can look like How to properly diagnose histamine intolerance What you can do to support your liver if you have histamine intolerance How to do a low-histamine diet the right way How food freshness affects histamine levels The histamine-migraine connection What research is showing about histamine’s role in the vestibular system and inner ear How addressing histamine can make previous treatments that didn't work suddenly start working When there’s too much histamine in the body than what the body can actively remove, you’ll have more histamine reactions and a harder time processing histamine in general. I want you to remember though that all hope is not lost! For additional support, we have the webinar with Isabel Smith that touches on histamine intolerance, as well as liver and gut support inside Vestibular Group Fit.  We will also have Natalie Sampson, a Board Certified Genetic Counselor, joining me on a future podcast episode! Links Mentioned: Vestibular Group Fit (code GROUNDED at checkout for 15% off!): https://thevertigodoctor.com/vestibular-group-fit Free Resources: ⁠The 4 Steps to Managing Vestibular Migraine: https://thevertigodoctor.myflodesk.com/cb5js0y78n ⁠The PPPD Management Masterclass⁠: https://thevertigodoctor.myflodesk.com/new-pppd ⁠What your Partner Should Know About Living with Dizziness⁠: https://thevertigodoctor.myflodesk.com/partnership ⁠The FREE Mini VGFit Workout⁠: https://thevertigodoctor.myflodesk.com/minifit ⁠The FREE POTS – safe Workouts⁠: https://thevertigodoctor.myflodesk.com/pots Connect with Dr. Madison (@TheVertigoDoctor): https://instagram.com/thevertigodoctor Work with Dr. Madison: For 1:1 Vestibular Rehabilitation Therapy, email madison@thevertigodoctor.com Otherwise, I'll see ya in Vestibular Group Fit! Connect with Dr. Jenna (@dizzy.rehab.therapist): https://www.instagram.com/dizzy.rehab.therapist/ Learn about the Oak Method: http://thevertigodoctor.com/why-vestibular-group-fit Love what you heard?Consider leaving a review on your favorite podcast platform to help us reach more vestibular warriors like you! This podcast is for informational purposes only and may not be the best fit for you and your personal situation. It shall not be construed as medical advice. The information and education provided here is not intended or implied to supplement or replace professional medical treatment, advice, and/or diagnosis. Always check with your own physician or medical professional before trying or implementing any information read here. Citations Cleveland Clinic. “Histamine.” Cleveland Clinic, Cleveland Clinic, 28 Mar. 2023, https://my.clevelandclinic.org/health/articles/24854-histamine. Accessed 10 July 2026. Jochum C. (2024). Histamine Intolerance: Symptoms, Diagnosis, and Beyond. Nutrients, 16(8), 1219. https://doi.org/10.3390/nu16081219  Sánchez-Pérez S, Comas-Basté O, Duelo A, Veciana-Nogués MT, Berlanga M, Vidal-Carou MC and Latorre-Moratalla ML (2022) The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine intolerant women. A pilot study. Front. Nutr. 9:1018463. doi: 10.3389/fnut.2022.1018463 Jackson, K., Busse, W., Gálvez-Martín, P., Terradillos, A., & Martínez-Puig, D. (2025). Evidence for Dietary Management of Histamine Intolerance. International journal of molecular sciences, 26(18), 9198. https://doi.org/10.3390/ijms26189198 Kong, L., Domarecka, E., & Szczepek, A. J. (2023). Histamine and Its Receptors in the Mammalian Inner Ear: A Scoping Review. Brain sciences, 13(7), 1101. https://doi.org/10.3390/brainsci13071101  Tighilet, B., Trico, J., Marouane, E., Zwergal, A., & Chabbert, C. (2024). Histaminergic System and Vestibular Function in Normal and Pathological Conditions. Current neuropharmacology, 22(11), 1826–1845. https://doi.org/10.2174/1570159X22666240319123151  Chen, Z. P., Zhang, X. Y., Peng, S. Y., Yang, Z. Q., Wang, Y. B., Zhang, Y. X., Chen, X., Wang, J. J., & Zhu, J. N. (2019). Histamine H1 Receptor Contributes to Vestibular Compensation. The Journal of neuroscience : the official journal of the Society for Neuroscience, 39(3), 420–433. https://doi.org/10.1523/JNEUROSCI.1350-18.2018  Ferretti, A., Gatto, M., Velardi, M., Di Nardo, G., Foiadelli, T., Terrin, G., Cecili, M., Raucci, U., Valeriani, M., & Parisi, P. (2023). Migraine, Allergy, and Histamine: Is There a Link?. Journal of clinical medicine, 12(10), 3566. https://doi.org/10.3390/jcm12103566  histamine and vestibular conditions, vestibular migraine, chronic dizziness, migraine attacks, vestibular disorders, vestibular group fit, food sensitivities, MCAS, gut issues, holistic approach, bucket theory, lifestyle changes, allergies and vestibular disorders

Our daily choices can shape not only how long we live, but how well we live. Dr. Michael Roizen challenges us to rethink aging by exploring how nutrition, movement, prevention, and personal motivation can influence our health trajectory.  Drawing from decades of medical experience and longevity research, Dr. Roizen shares why finding your personal "why" is essential to lasting change and how wellness can benefit individuals, families, and communities. His message is hopeful and empowering: we can take meaningful steps today to live younger, longer, and with greater purpose.  Key Takeaways:   Our daily choices around nutrition, movement, tobacco, stress, and other lifestyle factors can significantly influence our health trajectory and quality of life.   Finding your personal motivator is essential because lasting behavior change becomes more meaningful when it connects to something you genuinely care about.   Staying well is not only a personal responsibility but can also contribute to healthier families, stronger communities, and a more sustainable healthcare system.   Wellness programs can create meaningful change when organizations make healthy choices easier and support people in building sustainable habits.   Longevity science is rapidly evolving, giving us new opportunities to extend not just lifespan but the number of years we can live with strength, independence, and purpose.   We couldn't highlight incredible stories like this without the support of our sponsor, CommunityAmerica Credit Union. Thank you for helping us promote connection, well-being, and stronger communities. If you're looking for trusted financial wellbeing resources, we invite you to connect with their team and take the next step toward greater financial confidence.  About Dr. Michael Roizen:  Dr. Roizen served as Cleveland Clinic's first Chief Wellness Officer from 2007 to 2019 & founding Chair of its Wellness Institute. The Clinic's Wellness Programs helped the clinic not spend over 1.250 billion dollars for its 101,000 employees & dependents over 11 years compared with national averages and help over 43.6% of participants achieve 6 normals+2 ® for health. This reduced their rate of aging and time of disability equivalent to 12.5 years over an 80 year lifespan.   Dr Roizen is a recipient of an Emmy, an Elle, the Paul Rogers best medical communicator award from the National Library of Medicine, & the Bennett Family Award from GlobalWellnesSummit. He initiated & developed the RealAge concept to motivate behavior change. That started the concept that 60 could be the new 40. He believes that soon 90 will be the new 40—how you can prepare for it is described in his recently released book and app-newsletter, The Great Age Reboot and 4 YOUngevity.com Ai coaching program & free newsletter.   He has authored over 195 peer reviewed scientific publications (he really is a science nerd), four New York Times #1 best sellers, 9 overall top 10 bestsellers including his initial #1 Bestseller in 5 countries, "RealAge: Are You As Young As You Can Be?", "AgeProof—Living Longer without breaking a hip or running out of money" and his book that displaced Harry Potter from #1 on Amazon for 177 days, YOU: On A Diet, The Owner's Manual for Waist Management. He served 16 years on FDA advisory committees, including chairing one for two years. His books have been translated into 44 languages and been number 1 in 5 countries in addition to the USA. He helped start 14 companies including his current Therapeutic Plasma Exchange Company, Lifespan-Edge.com, , co-invented a drug approved by the FDA, co-invented the Cloud (US Patent # 2004/0205055A1 ; his coinventor –who took it from him—was just awarded 673 million dollars from Amazon)and has a weekly podcast now in its 1268th+ week; he and Dr Oz coauthored a daily column syndicated to over 68 newspapers that translates current scientific reports into actionable steps for lay audiences. When Dr Oz declared his candidacy for public office, Dr Roizen has continued the column alone, but have recently started writing it together again, but he has restarted alone as Dr Oz is now USA's CMS Director-Administrator.   He is a recipient of The United Way of Cleveland Humanitarian of the Year Award. He has won over 75 trophies in class A squash competition. His wife is a developmental pediatrician also listed in the Best Doctors in America. The Roizens have two children: Jenny, a PhD organic chemist working for the US Energy Department, and Jeffrey, an MD/PhD faculty member in pediatric endocrinology at Children's Hospital of Philadelphia. Dr. Roizen is devoted to helping people live younger. He consults with patients in Cleveland Clinic's Executive Health and Wellness Programs. He teaches them the 80% likelihood that they can be 40 at calendar age 90, and how to prepare for that.  Connect with Dr. Michael Roizen at:  https://4youngevity.com/    https://lifespan-edge.com/   Connect with Dr. Michelle and Bayleigh at:  https://smallchangesbigshifts.com  hello@smallchangesbigshifts.com  https://www.linkedin.com/company/smallchangesbigshifts  https://www.facebook.com/SmallChangesBigShifts  https://www.instagram.com/smallchangesbigshiftsco  https://www.youtube.com/@smallchangesbigshiftsco    Thanks for listening!  Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page.  Do you have some feedback or questions about this episode? Leave a comment in the section below!  Subscribe to the podcast  If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can also subscribe in your favorite podcast app.  Leave us an Apple Podcasts review  Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts. 

Ultra-processed foods' impact on postpartum depression/psychosisWhich should my sister take, Jardiance or Dapagliflozen?  I had aortic valve repair. Can I safely take N101?I suffer with trigeminal neuralgia after recent extensive dental work. What do you advise?What would be the optimal total testosterone level for an 84 year old male?

Jon Canarick has spent 25 years investing in gyms, and he's still trying to explain why doctors won't write a prescription for exercise. As Managing Partner at North Castle Partners, he helped build Equinox, turned around Curves, and backed Barry's long before boutique fitness was a category. Canarick walks through what actually changed in fitness private equity since he joined North Castle in 2001, from the corporate franchise wave that built 24 Hour Fitness and LA Fitness to Planet Fitness's pricing model, which he credits with pulling more Americans into gym memberships than anything else in the last quarter century. He details the failed attempt to combine Curves with Jenny Craig and a Cleveland Clinic nutrition program, a bet he calls a real failure despite the medical credibility behind it. Canarick also breaks down why GLP-1 drugs are reshaping the industry at the premium end through brands like Monarch and Miora, and why an LEK study showing 30% of big box gym members also pay for boutique fitness complicates the usual story about a shrinking middle class of gyms. Jon Canarick is Managing Partner at North Castle Partners, a private equity firm focused exclusively on healthy, active, and sustainable living businesses, where he has sat on the boards of Equinox, Curves, Barry's, Therabody, and SLT. Website: https://northcastlepartners.com | LinkedIn: linkedin.com/in/jon-canarick-4340362 Get Eric's weekly industry newsletter: https://futureoffitness.co Watch full episodes on YouTube: https://www.youtube.com/@futureofofitnesspod OUR SPONSORS:

The Cleveland Clinic is ranked the #2 hospital in the world, renowned for cardiology and heart surgery. Imagine going there with a serious heart issue—you'd have brilliant surgeons, skilled nurses, advanced imaging, and the best care available. But the most important part of that hospital isn't what you see; it's what you don't see: the power plant. No matter how great the surgeons or how advanced the equipment, if the power plant fails, nothing can be done. The hospital becomes no more valuable than a cabin in the woods.

Dr. Toby Cosgrove is the former President and CEO of Cleveland Clinic, where he now serves as Executive Advisor. A cardiac surgeon and inventor, he is a member of the Cleveland Medical Hall of Fame and the Cleveland Business Hall of Fame, and has addressed the World Economic Forum at Davos and the Senate HELP Committee. In this episode of DGTL Voices, Toby tells Edward Marx about nearly flunking out of Williams College before anyone discovered he was dyslexic, running a hundred-bed casualty staging flight in Vietnam at 28, and the two decisions he's proudest of from his tenure at Cleveland Clinic, both about purpose and language rather than buildings. Plus: the three problems he thinks AI has to solve in healthcare, and his advice for people who want the C-suite. Connect with Marx Advisory at https://bio.marxadvisory.com/

Sen. Jon Husted spoke to Bill about being at Kent State University's Independence Campus and the Cleveland Clinic today - visiting Stark State College's CDL training center - Ohio father who doubled his pay after completing five weeks of CDL training - Midterms

What happens when a Cleveland Clinic internist and mother of three develops chest pain and the diagnosis is just stress? For Dr. Beth Ricanati, the prescription wasn't another pill. It was a bowl of dough. On a friend's Rosh Hashanah suggestion - "Why don't you make challah?" - she spent an afternoon with 6 ingredients. Beeper off, hands in dough for 20 minutes, she finally stopped. And felt better. That one Friday loaf became a ritual, then 100+ workshops, and now her new book The Braided Prescription. Beth joins Bill to explain why challah isn't about challah - it's about ritual vs. routine, "challah diplomacy," and how lifestyle medicine impacts 75-80% of chronic disease. Not a replacement for medicine, but the essential addendum.Get your copy of The Braided Prescription by Dr. Beth Ricanati As an Amazon Associate, Now I've Heard Everything may earn a commission from qualifying purchases.Chapters:00:00 Introduction to Beth Ricanati and her new book 02:07 Beth's journey from stress to wellness 04:02 The significance of making hala as a ritual 05:49 The connection between bread-making and meditation 08:10 Universal nature of rituals and their impact 10:02 The power of bread as a symbol of connection 11:54 The role of lifestyle medicine and traditional practices 14:02 How Beth's children embrace the ritual 16:01 Creative ways to personalize bread-making 17:55 Closing thoughts and practical tipsGuest InformationDr. Beth RicanatiWebsiteSocial:YouTube Facebook Instagram For more intriguing and engaging interviews each week, subscribe now on:Spotify Apple Podcasts YouTube

Wise men and women remind us that life is a marathon, and not a sprint. Joining us this week is Benji Wilkins. Benji is a magician in the U.K., and for 42 days this summer, his life was quite literally a marathon. In the process, Benji raised money to help his mom, who lives with MS, and he raised awareness of MS across the U.K. and around the world.   We're also sharing results of a study that focused on gait training using a powered exoskeleton for people living with MS. We'll tell you how you can participate in the MOMENT-MS study and help researchers develop a smartphone app that takes a novel approach to managing MS-related pain. And we're reminding you to register for ECTRIMS Patient Community Day. It's your opportunity to participate in the largest MS research conference in the world! We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Running a marathon a day (when you're not a runner) for MS  :22 Cleveland Clinic researchers look at gait training using a powered exoskeleton for people with MS  1:02 University of Washington researchers are developing an app to manage MS pain using mindfulness-based cognitive therapy. And you can help them!   6:53 Sign up to participate in the largest MS research conference in the world   5:27 Benji Wilkins describes what it's like to run 42 marathons in 42 days on behalf of his mom, who lives with MS  6:53  Share this episode  29:01 Next week  29:20 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/470 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com STUDY: Feasibility and Outcomes of Gait Training With a Powered Exoskeleton in Individuals With Multiple Sclerosis https://pubmed.ncbi.nlm.nih.gov/40465831 SUPPORT: Marathons For Mum Web: https://marathonsformum.com Instagram: https://instagram.com/benjitwilkins PARTICIPATE: MOMENT-MS Study Web:   https://uwmsrehabwell.org/moment-ms Email: momentms@uw.edu Video: https://www.youtube.com/watch?v=Z6TA5-9dy7s REGISTER: ECTRIMS Patient Community Dayhttps://ectrimspatientcommunity.eu JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 470 Guest: Benji Wilkins Privacy Policy

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET).   Join us as we delved into: The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and managing these conditions Treatment options for PV, including hydroxyurea, ropeginterferon alfa-2b, and ruxolitinib, as well as the approval of rusfertide The importance of risk stratification based on patient age and history of thrombosis The management of side effects associated with various treatment options The clinical utility of monitoring JAK2 allele burden and its implications for patient management Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease   Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers  ⁠Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care! #PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

In this TopMedTalk perioperative profile, host Andy Cumpstey interviews Professor Dan Sessler, Vice President for Clinical and Outcomes Research and Professor of Anesthesiology and Biostatistics at UTHealth Houston (McGovern Medical School), about his career as a perioperative trialist with over 1,000 publications. Sessler describes his scientific family background, early inspiration from clinical trials through Henry Kaplan's Hodgkin's work, and a shift from planned pediatric oncology to anesthesiology. He recounts building a research career starting with perioperative thermoregulation at UCLA and UCSF, then expanding into broad outcomes research, ultimately founding a large Department of Outcomes Research at the Cleveland Clinic and advocating for large multicenter trials. He emphasizes mentorship, philanthropy, and his current focus on reducing postoperative mortality through better ward monitoring and prevention beyond "failure to rescue." - The 2026 International Practicum on Cardiopulmonary Exercise Testing will be held at the Balmer Lawn Hotel in Brockenhurst, UK, from September 16th to 18th this year. It is organised by iPOETTS , the international perioperative testing and training society. Come and join us at this premier educational event designed for clinicians, scientists, and healthcare professionals interested in sport, exercise, and perioperative medicine. This is an International Perioperative Testing and Training Society accredited event so when you attend you can get your iPOETTS accreditation, showing that you are a practitioner who has reached a high, standardized level of competence in performing and interpreting Cardiopulmonary Exercise Testing (CPET) for patients preparing for major surgery. Go now to http://www.ebpom.org

According to The Cleveland Clinic, around one in four people are affected by bad breath. It's also known as halitosis and bad breath can be a source of embarrassment. It's sometimes caused by consuming certain well-known foods, like garlic, onion, cheese, and coffee for example.  But it can also be a symptom of an underlying health condition, such as pneumonia, gum recession, kidney disease and gastrointestinal disorders. Do bacteria have anything to do with it? How can we avoid bad breath? In under 3 minutes, we answer your questions ! To listen to the latest episodes, click here: ⁠⁠⁠Why do our stomachs rumble?⁠⁠⁠ ⁠⁠⁠Why does hair turn grey?⁠⁠⁠ ⁠⁠⁠What does it mean to be a seenager?⁠⁠⁠ A Bababam Originals podcast written and realised by Joseph Chance. First Broadcast: 21/5/2023 Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, a look at what you can do if you have excessive startle response or you are extra jumpy around certain sounds or experiences.  Resources Mentioned:    What to Eat for Better Mental Health on the Sutter Health website.   Cleveland Clinic on Eat These Foods to Reduce Stress and Anxiety The Mayo Clinic FAQ on coping with anxiety. Harvard Sleep Medicine page on Sleep Hygiene and a page on Progressive Muscle Relaxation for Sleep.   For U.S. Armed Forces service members, the Red Cross has a PDF on setting up a sleep routine   Australian Center for Clinical Interventions web page on Progressive Muscle Relaxation   Emergency Resources The Trevor Project: Provides crisis support specifically for LGBTQ+ youth through phone (1-866-488-7386), text (START to 678-678), and online chat. Available 24/7. They also provide peer support and community.    Veterans Crisis Line: Call 988 and press 1, text 838255, or chat online. There are phone lines for those serving overseas. Visit the website to find the current status of the Veteran line and international calling options.    National Crisis Text Line: Text HOME to 741741 for free, confidential support 24/7. This service operates independently of the 988 service. Users can use text, chat or WhatsApp as a means of contact.   Disclaimer:  Links to other sites are provided for information purposes only and do not constitute endorsements.  Always seek the advice of a qualified health provider with questions you may have regarding a medical or mental health disorder. This blog and podcast is intended for informational and educational purposes only. Nothing in this program is intended to be a substitute for professional psychological, psychiatric or medical advice, diagnosis, or treatment.  

Thanks to our Partners: NAPA TRACS, Today's Class, KUKUI, and Pit Crew Loyalty Watch Full Video Episode What if your auto repair shop could help advance breast cancer research while growing your business? Co-founders Leigh Anne Best and Laura Frank, alongside Dr. Justin Johnson from the Cleveland Clinic, share the story behind one of the automotive industry's most impactful grassroots fundraisers. Since 2011, participating shops have partnered with parts vendors to provide free brake pads during October, helping customers save on repairs while shops donate 10% of the total service cost to breast cancer vaccine research at Cleveland Clinic. With $2.4 million raised and a $3 million milestone in sight, the campaign is helping fund continued research into the alpha-lactalbumin breast cancer vaccine for triple-negative breast cancer while giving independent repair shops an opportunity to strengthen their communities and grow their business. What You'll Learn How the Brakes for Breasts win-win fundraising model works.How participating shops can partner with parts vendors and customers.Why 100% of donations go directly to the research laboratory.How grassroots funding helped keep the Cleveland Clinic research lab open after Dr. Vincent Tuohy's passing.What Phase 1 vaccine research revealed and what Phase 2 will require.How participating shops can generate community awareness and increased car count.How your shop can participate and access promotional resources. Brakes for Breasts demonstrates what can happen when the automotive industry comes together around a cause. Shops can serve their customers, strengthen their communities, grow their businesses, and help fund research that could change lives. Every shop, every customer, and every dollar can make a difference. https://www.brakesforbreasts.com/ The First Breast Cancer Vaccine Trial Recipient Jennifer Davis: https://remarkableresults.biz/remarkable-results-radio-podcast/cc111/ NAPA TRACS will move your shop into the SMS fast lane with onsite training, six days a week of support, and local representation. http://napatracs.com/ Optimize training with Today's Class: In just 5 minutes daily, boost knowledge retention and improve team performance. https://www.todaysclass.com/ Stop juggling multiple marketing tools. KUKUI's integrated platform delivers 4x better website conversions, automated follow-up, and real-time ROI tracking. https://www.kukui.com/ You're probably tired of chasing new customers who never return. Pit Crew Loyalty ends the one-and-done cycle, turning first visits into lasting, reliable revenue at https://www.pitcrewloyalty.com/ Connect with the Podcast: Download and Listen on Our Mobile App: https://automotiverepairpodcastnetwork.com/app/Visit the Website:https://remarkableresults.biz/Subscribe on YouTube:https://www.youtube.com/carmcapriottoFollow on Facebook:https://www.facebook.com/RemarkableResultsRadioPodcast/Follow on LinkedIn:https://www.linkedin.com/in/carmcapriotto/Follow on Instagram:https://www.instagram.com/remarkableresultsradiopodcast/Join Our Virtual Toastmasters Club:https://remarkableresults.biz/toastmastersJoin Our Private Facebook Community:https://www.facebook.com/groups/1734687266778976Join our Insider List:https://remarkableresults.biz/insiderAll books mentioned on our podcasts:https://remarkableresults.biz/booksOur Classroom page for personal or team learning:https://remarkableresults.biz/classroomBuy Me a Coffee:https://www.buymeacoffee.com/carmSpecial episode collections:https://remarkableresults.biz/collections The Automotive Repair Podcast Network:

Beulah was such a prolific inventor in the early 20th century that the press nicknamed her Lady Edison. She was an outlier as an unmarried woman who got her foot in the door as an inventor by pounding the pavement in 1920s New York. Research: Bengtson, Harlan H. “Beulah Louise Henry.” EBSCO. 2021. https://www.ebsco.com/research-starters/history/beulah-louise-henry “Beulah Louise Henry.” National Inventors Hall of Fame. https://www.invent.org/inductees/beulah-louise-henry Dick, Gerry. “Beulah henry Sits in Chiffon Laboratory Inventing Almost Everything But Excuses.” The Rockford Argus. April 8. 1937. https://www.newspapers.com/image/531344097/?match=1&terms=%22Beulah%20Henry%22&search-id=22e1b59c-1edb-4d9c-895d-9454b6343852&search-rank=7 Hart, Alicia. “Meet Beulah henry, the Inventor.” The Salisbury Post. Sept. 1, 1955. https://www.newspapers.com/image/1026874682/?match=1&terms=%22Beulah%20Henry%22&search-id=be53d62d-90f0-4084-8868-9b0e0a4dbb37&search-rank=3 Henry, B.L. “DOUBLE CHAIN STITCH SEWING MACHINE.” April 21, 1936. https://ppubs.uspto.gov/api/pdf/downloadPdf/US-2037901-A?source=USPAT&requestToken=eyJzdWIiOiI4NTA2NjMxNi1kZTRmLTRlNzQtOGJhYS1kYTRjMzhhMGZkNmYiLCJ2ZXIiOiJjY2M5MGE0NS02ZGRhLTQ5YTAtOTQzZS1lOTIyMzBhMjI0MjEiLCJleHAiOjB9 Henry, B.L. “DUPLICATING ATTACHMENT FOR TYPEWRITERS.” Aug. 30, 1932. https://patentimages.storage.googleapis.com/e7/a5/7d/a7e3bbcd163f09/US1874749.pdf Henry, B.L. “Hand Bag.” U.S. Patent Office. May 27, 1913. https://patentimages.storage.googleapis.com/0a/6d/16/4d8139d4025580/US1063031.pdf Henry, B.L. “Ice Cream Freezer.” U.S. Patent Office. Sept. 3, 1912. https://patentimages.storage.googleapis.com/dc/d8/5c/1c61ca65b0339b/US1037762.pdf Henry, B.L. “Indicator Top.” U.S. Patent Office. March 2, 1926. https://ppubs.uspto.gov/api/pdf/downloadPdf/US-1575264-A?source=USPAT&requestToken=eyJzdWIiOiIxMzU2NTdlNi03OWNkLTQyZGUtYTgwNi0yYzRhYmM3OGU5OGIiLCJ2ZXIiOiI2MzIxNTg0Yy1iOTZjLTRhYmItOTZhNC04OGUxNTI3ODY3NjUiLCJleHAiOjB9 Henry, B.L. “Parasol.” U.S. Patent Office. Nov. 18, 1913. https://patentimages.storage.googleapis.com/6e/fe/25/726c19533c2b0f/US1079240.pdf Henry, B.L. “Parasol.” U.S. Patent Office. May 6, 1924. https://patentimages.storage.googleapis.com/5c/ad/88/868b750b1d9c44/US1492725.pdf Henry, B.L. “Radio Doll.” U.S. Patent Office. Dec. 8, 1925. https://ppubs.uspto.gov/api/pdf/downloadPdf/US-1565145-A?source=USPAT&requestToken=eyJzdWIiOiJhMTUwM2E5YS04MzYzLTRmYTgtYjRmOS1lZDU5OGIyMDllNGEiLCJ2ZXIiOiI2MjZkN2M5OS05OGVkLTQzY2EtOGE2YS02NTU2ZWIzYzY0MzgiLCJleHAiOjB9 Henry, B.L. “SEAM AND METHOD OF FORMING SEAMS.” U.S. Patent Office. Feb 4. 1941. https://ppubs.uspto.gov/api/pdf/downloadPdf/US-2230896-A?source=USPAT&requestToken=eyJzdWIiOiI4NTA2NjMxNi1kZTRmLTRlNzQtOGJhYS1kYTRjMzhhMGZkNmYiLCJ2ZXIiOiJjY2M5MGE0NS02ZGRhLTQ5YTAtOTQzZS1lOTIyMzBhMjI0MjEiLCJleHAiOjB9 Henry, B.L. “Simulated Dispensing Device.” U.S. Patent Office. Dec. 11, 1951. https://patentimages.storage.googleapis.com/6d/80/75/d6a9df36c75df0/US2577849.pdf Henry, B.L. “Water Sport Apparatus.” U.S. Patent Office. August 16, 1927. https://ppubs.uspto.gov/api/pdf/downloadPdf/US-1639607-A?source=USPAT&requestToken=eyJzdWIiOiIxMzU2NTdlNi03OWNkLTQyZGUtYTgwNi0yYzRhYmM3OGU5OGIiLCJ2ZXIiOiI2MzIxNTg0Yy1iOTZjLTRhYmItOTZhNC04OGUxNTI3ODY3NjUiLCJleHAiOjB9 Jones, Stacy. “A Single Unit Serves for Mailing and Also Returning.” New York Times. Jan. 27, 1962. https://timesmachine.nytimes.com/timesmachine/1962/01/27/90129637.pdf?pdf_redirect=true&ip=0 LaRiccia, Dante. “Electricity Consumption: Culture, Gender and Power.” Energy History Online. Yale University. https://energyhistory.yale.edu/electricity-consumption-culture-gender-and-power/ Mydans, Seth. “Overlooked No More: Beulah Henry, Inventor With an Endless Imagination.” New York Times. March 14, 2025. https://www.nytimes.com/2025/03/14/obituaries/beulah-henry-overlooked.html “Synesthesia.” Cleveland Clinic. May 3, 2023. https://my.clevelandclinic.org/health/symptoms/24995-synesthesia “"There's a better way of doing that." USPTO. https://www.uspto.gov/learning-and-resources/journeys-innovation/historical-stories/theres-better-way-doing See omnystudio.com/listener for privacy information.

Recent research shows that between 40 and 60% of women either change or quit their sport due to bladder leaks. That's 100% too many in our book. So this week we sat down with Dr. Lauren Siff, a double board-certified urogynecologist to demystify one of women's health's most under-discussed issues: urinary leakage. We break down the differences between stress and urge incontinence, why athletes and active women are prone to leaking, and how the menopausal transition can worsen the situation through declining estrogen, shifting vaginal pH, and rising UTI risk. Dr. Siff walks us through the full range of solutions, from pelvic floor exercises and support devices to Botox, bladder stimulators, and the game-changing role of vaginal estrogen, plus how to know when it's time to seek care. Her message is loud and clear in this one: no matter how small or severe the symptoms, there's help available — and you never have to stop doing what you love.Dr. Siff is a double board-certified urogynecologist and Chief of Gynecology and Urogynecology for the Central Virginia VA Health Care System and Associate Professor at VCU School of Medicine and VCU Institute of Engineering. A dedicated innovator and surgical educator — with a Distinguished Educator certificate from the Cleveland Clinic and founder of SurgicalEd VR, which uses VR and haptic technology to improve the quality, safety, cost-effectiveness, and accessibility of surgical training. She also serves board and committee roles with the Society for Gynecologic Surgeons, American Urogynecologic Society, and American Association of GYN Laparoscopists. She is Central Virginia Site Lead for the National VA Women's Health Research Network, and chairman of the U.S. National Surgery Office's Surgical Advisory Board for GYN. Philanthropically, she directs surgeon training for Global Surgical Expedition, driven by a mission to democratize access to surgical training and vital surgical procedures worldwide.FeistyFit Info: https://livefeisty.com/training/running/feistyfitfall/Join us at Feisty Fest September 18-20, 2026: https://livefeisty.com/events/feisty-fest/Women's Mechanic Camp in Tucson: https://livefeisty.com/events/bike-mechanic-school-tucson/Courses and Coaching: https://livefeisty.com/courses/Sign up for our FREE Feisty 40+ newsletter: https://livefeisty.com/newsletters/feisty-40/Follow Us on Instagram:Feisty Menopause: @feistymenopauseHit Play Not Pause Facebook Group: https://www.facebook.com/groups/807943973376099Support our Partners:Midi Health: You Deserve to Feel Great. Book your virtual visit today at https://www.joinmidi.com/Previnex: Get 15% off your order with code HITPLAY at https://www.previnex.com/ Wahoo: Use the code FEISTY2026 to get a free Headwind Smart Fan (value $300) with the purchase of a Wahoo KICKR RUN at https://shorturl.at/WVhdr

There are various types of inhalers, but how do you use them to ensure the treatment is given effectively? Improper use of inhalers is more common than you might think. Registered respiratory therapist Givenchy Ayisi-Boahene, NYU Langone and host Amy Attaway, MD, Cleveland Clinic, walk through the difference between the various types of inhalers, common mistakes patients make in using each, and other tips for managing asthma.

Paul Lunter didn't start out trying to build a wellness empire — he was in construction, watched someone in pain step in and out of the shower for relief, and built a machine instead. Thirty-seven years later, that machine (HydroMassage) has grown into WellnessSpace Brands: five product lines, 400 million sessions delivered, and installations in 50+ countries at Planet Fitness, Life Time, Gold's Gym, and beyond. Lunter walks Eric Malzone through the company's medical-market origins, the R&D behind machines like the PolarWave Dry Plunge and the company's newest RedZone sauna which uses no wood, and why he thinks recovery is a permanent industry shift rather than another fitness fad. Key Takeaways

For women facing radical cystectomy, removing the bladder doesn't always have to mean removing reproductive organs as well. In this episode of Bladder Cancer Matters, host Rick Bangs talks with Cleveland Clinic urologic oncologist Dr. Rebecca Campbell about organ-sparing radical cystectomy and how, for carefully selected patients, surgeons may be able to preserve the vagina, uterus and ovaries while still prioritizing effective cancer treatment. Dr. Campbell explains who may be a candidate, how organ sparing can help protect sexual function, hormonal health, continence and overall quality of life and why women should feel empowered to ask their surgeon about their options—or seek a second opinion if those options aren't discussed. It's an important conversation about looking beyond bladder removal to the life a patient wants to live after treatment.

In this episode of the Fit Father Project Podcast, I make the case for the single most powerful longevity lever in exercise science: Cardiovascular training.Pulling from major studies out of the Cleveland Clinic, the VA, and Copenhagen, I explain why VO2 max — your body's ability to take in and use oxygen — is a stronger predictor of how long you'll live than your weight, cholesterol, or even your muscle mass.I state this clearly: This isn't an argument against lifting. Strength training is non-negotiable for your bones, blood sugar, and independence as you age. But I break down the research showing that muscle alone doesn't train your mitochondria — the power plants inside every cell — the way cardiovascular work does.I walk you through exactly how much cardio you actually need, the different types (zone two, intervals, all-out sprints), and how to fit all of it around the strength training you're already doing inside the Fit Father programs.If you've been all-in on lifting and protein but ignoring your heart and lungs, this episode will change how you think about your training for the rest of your life.Rate & Review — If this episode changed how you think about your training, please take a moment to rate and review the Fit Father Project Podcast. Your review helps more men over 40 find the show and the tools they need to build strength, energy, and long-term health.Join the Fit Father Community — If you want help putting this into action with real accountability, join us inside the Fit Father Project. We'll help you build a training plan that covers strength, cardio, and everything in between — built specifically for busy dads over 40.Key TakeawaysVO2 max — the maximum oxygen your body can take in and use — is the strongest predictor of longevity ever measured, ahead of weight, cholesterol, or muscle massCleveland Clinic study (122,000 adults, 8.4-year follow-up): the fitter you were, the longer you lived, with no ceiling — the fittest people lived the longestVA study of 750,000 veterans: every 1 MET increase in fitness meant a 13-15% drop in death risk, regardless of age, weight, sex, or existing diseaseCopenhagen study (46-year follow-up): each 1-unit increase in VO2 max was linked to roughly 45 extra days of lifeVO2 max naturally declines about 10% per decade after age 30 — cardio training is one of the best ways to slow that declineMayo Clinic study: strength training alone improved lean mass and blood sugar, but only cardio and combined groups improved aerobic capacity and mitochondrial functionAdults age 65-80 saw even bigger mitochondrial gains (69%) than younger adults (49%) from cardio intervals — it's never too late to startWalking is valuable, but mortality benefits plateau around 6,000-8,000 steps a day — steps alone won't create the mitochondrial adaptations cardio doesThe weekly target: 2-3 hours of strength training, 150-200 minutes of zone two cardio, 1-2 hard intervals near 80% max heart rate, and one all-out explosive effortYou can be muscular, lean, and still have poor cardiovascular health — muscle and mitochondrial fitness are largely independent, and both need direct trainingSupport Your Mitochondria with BEAM MineralsYour mitochondria need key minerals — magnesium, iron, copper, and zinc — to actually generate the energy your body runs on. BEAM Minerals is a liquid mineral supplement Dr. Anthony takes daily for steadier energy and better recovery. Head to beamminerals.com/fitfamily and use code FITFAMILY for 20% off your first order.Want To Change Your Life? Check Out FF30X!FF30X is a simple, sustainable, and specific weight loss program designed especially for busy men over 40.With short metabolic workouts, an easy-to-follow meal plan, and an accountability team there for you every step of the way, FF30X can help you lose weight, regain energy and vitality, and live life to the fullest. Click here to see everything you get when you join FF30X.*Please know that weight loss results and health changes/improvements vary individually; you may not achieve similar results. Always consult with your doctor before making health decisions. This is not medical advice - simply very well-researched information on longevity training, muscle health, and healthy aging.

Dr. Hooman Rashidi is Associate Dean of AI in Medicine at the University of Pittsburgh and Executive Director of CPACE. Before Pitt, he founded Cleveland Clinic's Center for AI and Data Science and directed AI at UC Davis Medical Center. Ed asks him whether medical staff are prepared for AI. His answer is that even the ones who feel ready are not, because people bundle every kind of AI together and the newer generative tools don't behave like the predictive models the field has been using for decades. In this episode of DGTL Voices, he explains what's missing from tumor boards, why he leads with education before deployment, how Pitt runs a hybrid strategy rather than committing to vendors alone, and why his center puts junior contributors on patent filings when most institutions don't. https://bio.marxadvisory.com/

 There has been a sharp spike in silicosis diagnoses among workers who work with engineered stone countertops. The ATS released a report in 2026 on the subject, “Silicosis in the Artificial Stone Countertop Industry: An Official American Thoracic Society Workshop Report”. One of the report's authors Kristin Cummings, MD, MPH, California Department of Public Health, and expert Maeve McMurdo, MBChB, Cleveland Clinic, discuss why engineered stone can cause severe, rapidly progressive lung disease in young workers as well as the limitations of current workplace protections. On this episode of the ATS Breathe Easy podcast, they also highlight safer alternatives, the importance of recognizing occupational exposures, and what clinicians, employers, and consumers can do to help protect workers. Important resources: Read the full ATS report: https://pubmed.ncbi.nlm.nih.gov/42363709/ Failure of wet methods to control silica exposures: Soo et al. Respirable dust and respirable crystalline silica exposures among workers at stone countertop fabrication shops in Georgia from 2017 through 2023: https://pubmed.ncbi.nlm.nih.gov/40249150/ Prevalence of silicosis among Australian countertop workers: Hoy et al. Prevalence and risk factors for silicosis among a large cohort of stone benchtop industry workers https://pubmed.ncbi.nlm.nih.gov/37328266/Rapid progression of artificial stone silicosis after exposure cessation: Leon-Jimenez et al. Artificial Stone Silicosis: Rapid Progression Following Exposure Cessation: https://pubmed.ncbi.nlm.nih.gov/32563682/ California engineered stone silicosis dashboard (updated weekly): https://www.cdph.ca.gov/Programs/CCDPHP/DEODC/OHB/Pages/essdashboard.aspx 

What if food is doing far more than providing calories, protein, carbohydrates, and fat? What if every bite is actually delivering information to your genes, cells, microbiome, and biological systems? In this fascinating solo episode, Darin challenges the century-old idea of viewing food simply as fuel and explores what happens when we begin seeing food as biological information. From carrots resembling eyes and walnuts resembling brains to nutrigenomics, plant compounds, biophotons, structured water, living enzymes, and the microbiome, Darin dives into the hidden layers of food that never appear on a nutrition label. He explores established research alongside emerging and controversial areas of science, explaining why the freshness, color, diversity, and wholeness of what we eat may matter far beyond its calorie count. Darin also reveals why "eating the rainbow" is really about consuming a wider library of chemical information and why feeding your gut microbes may be just as important as feeding yourself. This episode will completely change the way you look at what's sitting on your plate. What You'll Learn Why Darin believes the calorie model leaves out some of food's most important biological effects How nutrients and plant compounds can influence gene expression through nutrigenomics and epigenetics Why Darin describes every meal as sending a "memo" to your DNA What biophotons are and the emerging research around light emitted by living cells and foods Why fresh, living foods may carry information that heavily processed foods have lost The theory of structured or "exclusion zone" water in living foods What happens to naturally occurring enzymes when foods are heated and processed Why the colors of fruits and vegetables correspond to different families of protective plant compounds How your food communicates with the trillions of microbes living inside your gut Why dietary diversity and fermented foods may help create a healthier, more resilient microbiome Chapters 00:00:00 – Welcome to SuperLife 00:00:32 – Sponsor: Bite 00:02:47 – The hidden clues sitting inside your food 00:03:22 – Carrots, tomatoes, and walnuts: coincidence or clues? 00:04:13 – Why we've been too busy counting calories 00:04:39 – Food is information 00:04:47 – Why the calorie model leaves out the bigger picture 00:05:14 – Your body isn't a furnace 00:05:48 – How food communicates with your cells 00:06:25 – Nutrigenomics: how food talks to your genes 00:06:53 – Every meal can influence gene expression 00:07:22 – What memo are you sending your DNA? 00:07:52 – The strange science of biophotons 00:09:03 – Why fresh food emits different light than processed food 00:09:37 – Where biophoton research stands scientifically 00:10:26 – Structured water and the fourth phase of water 00:12:00 – What processing may do to water inside food 00:12:37 – Sponsor: Manna Vitality 00:14:35 – The controversial theory of food enzymes 00:15:18 – What we know about enzymes in raw and sprouted foods 00:15:37 – The hidden information missing from nutrition labels 00:15:58 – Can the color of your food unlock your potential? 00:16:16 – Why "eat the rainbow" is chemistry, not mysticism 00:16:38 – Anthocyanins and the power of purple, red, and blue foods 00:17:27 – Color is the plant's natural label 00:18:20 – Every color sends your body a different message 00:18:50 – The problem with the modern "beige diet" 00:19:14 – You're feeding 38 trillion microbes, not just yourself 00:19:46 – How gut bacteria transform fiber into powerful compounds 00:20:25 – The extraordinary conversation between plants and your microbiome 00:21:05 – Why plant diversity matters for immunity, mood, and hormones 00:21:31 – The Stanford fermented food study 00:22:02 – What fermented foods did to microbiome diversity and inflammation 00:22:30 – Ultra-processed food, inflammation, and what's coming next 00:22:45 – Continue the full deep dive on Patreon 00:23:24 – Closing thoughts Thank You to Our Sponsors Bite Toothpaste: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order. Join the SuperLife Patreon: This is where Darin now shares the deeper work: - weekly voice notes - ingredient trackers - wellness challenges - extended conversations - community accountability - sovereignty practices Join now for only $7.49/month at https://patreon.com/darinolien Find More from Darin Olien: Website: darinolien.com Instagram: @darinolien Book: Fatal Conveniences Platform & Products: superlife.com New Show: Roadmap to Happiness Key Takeaway "Food isn't just fuel. Every bite carries information—through nutrients, plant compounds, color, fiber, enzymes, and the interactions it creates with your microbiome. Your body isn't simply counting calories; it's responding to biological signals. So the question isn't only how much you're eating. It's what message you're sending your body every time you sit down to eat." Bibliography/Sources: Food as Information & Nutrigenomics Dutton, R. (2017). Hey, Hippocrates: Food isn't medicine. It's just food. STAT News . https://www.statnews.com/2017/04/10/hippocrates-food-medicine/ Genes and diet in the prevention of chronic diseases in future generations. (n.d.). PubMed Central . https://pmc.ncbi.nlm.nih.gov/articles/PMC8900696/ Müller, M., et al. (2026). Nutrigenomics and the interface between diet and gene expression. ScienceDirect . https://www.sciencedirect.com/ Nutriepigenomics. (n.d.). In Wikipedia . https://en.wikipedia.org/wiki/Nutriepigenomics Stover, P. J., & Garza, C. (n.d.). Food as exposure: Nutritional epigenetics and the new metabolism. PubMed Central . https://pmc.ncbi.nlm.nih.gov/articles/PMC6486241/ Biophotons & Structured Water Bio-photons: The light in your cells, food & water. (n.d.). Watermatters . https://www.yourwatermatters.com/ Biophotons may shed new light on body and brain activity. (2025). Psychology Today . https://www.psychologytoday.com/ Pollack Laboratory. (n.d.). University of Washington. https://pollacklab.org/ Pollack, G. H. (2013). The fourth phase of water: Beyond solid, liquid, and vapor. Ebner & Sons Publishers . The legacy of light: Fritz-Albert Popp and the biomedical power of biophotons. (n.d.). Dr. Clark Store . https://drclarkstore.com/ Enzymes, Sprouting & Traditional Diets Characteristics of traditional diets. (n.d.). The Weston A. Price Foundation . https://www.westonaprice.org/ Edward Howell, MD. (n.d.). The Weston A. Price Foundation . https://www.westonaprice.org/ Germination: An alternative source to promote phytonutrients in edible seeds. (n.d.). Food Quality and Safety . https://academic.oup.com/fqs Howell, E. (1985). Enzyme nutrition: The food enzyme concept. Avery . Nutritional and end-use perspectives of sprouted grains: A comprehensive review. (2021). Food Science & Nutrition . https://onlinelibrary.wiley.com/doi/full/10.1002/fsn3.2477 Price, W. A. (1939). Nutrition and physical degeneration. Price-Pottenger Nutrition Foundation . Study on effect of germination on flavonoid content and nutritional value of different varieties of chickpeas. (2024). PubMed Central . https://pmc.ncbi.nlm.nih.gov/articles/PMC10787121/ Phytonutrients & Colors Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. (2017). Food & Nutrition Research . https://pmc.ncbi.nlm.nih.gov/articles/PMC5613902/ Anthocyanins as key phytochemicals acting for the prevention of metabolic diseases. (n.d.). PubMed Central . https://pmc.ncbi.nlm.nih.gov/articles/PMC6489379/ The therapeutic potential of anthocyanins: Current approaches based on their molecular mechanism of action. (2020). Frontiers in Pharmacology . https://www.frontiersin.org/articles/10.3389/fphar.2020.01300/full Microbiome, Fiber & Fermented Foods From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. (2016). Cell . https://www.cell.com/cell/fulltext/S0092-8674(16)30559-6 Stanford Medicine. (2021, July). Fermented-food diet increases microbiome diversity, decreases inflammatory proteins, study finds . https://med.stanford.edu/news/all-news/2021/07/fermented-food-diet-increases-microbiome-diversity-lowers-inflammation The mutual effect of dietary fiber and polyphenol on gut microbiota. (2025). ScienceDirect . https://www.sciencedirect.com/ Shape, Biomimicry & Botanical History Cardenas, D. (2013). Let not thy food be confused with thy medicine: The Hippocratic misquotation. e-SPEN Journal . https://doi.org/10.1016/j.clnme.2013.10.002 How do the 'three sister' plants work together? (n.d.). Soils Matter . https://soilsmatter.wordpress.com/ Kimmerer, R. W. (2013). Braiding sweetgrass: Indigenous wisdom, scientific knowledge, and the teachings of plants. Milkweed Editions . Nutritional benefits of lycopene and beta-carotene: A comprehensive overview. (n.d.). PubMed Central . https://pmc.ncbi.nlm.nih.gov/articles/PMC9317578/ The six tastes in Ayurveda: How rasa creates true satisfaction. (n.d.). Art of Living Retreat Center . https://artoflivingretreatcenter.org/ Three sisters farming: A model of regenerative agriculture. (n.d.). One Earth . https://www.oneearth.org/ Ultra-Processed Food & Meat Research Cleveland Clinic. (2018). Cleveland Clinic studies reveal role of red meat in gut bacteria, heart disease development . https://newsroom.clevelandclinic.org/ Hall, K. D., et al. (2019). Ultra-processed diets cause excess calorie intake and weight gain: An inpatient randomized controlled trial of ad libitum food intake. Cell Metabolism . https://doi.org/10.1016/j.cmet.2019.05.008 Harvard T.H. Chan School of Public Health. (2015). WHO report says eating processed meat is carcinogenic . https://www.hsph.harvard.edu/nutritionsource/2015/11/03/report-says-eating-processed-meat-is-carcinogenic-understanding-the-findings/ International Agency for Research on Cancer. (2015, October). Carcinogenicity of the consumption of red meat and processed meat. IARC Monographs Volume 114 . https://publications.iarc.fr/ The detrimental impact of ultra-processed foods on the human gut microbiome and gut barrier. (2025). Nutrients . https://www.mdpi.com/2072-6643/17/1 Ultra-processed foods and food additives in gut health and disease. (2024). Nature Reviews Gastroenterology & Hepatology . https://www.nature.com/articles/s41575-024-00898-3 Ultra-processed foods, gut microbiota, and inflammatory bowel disease: A critical review of emerging evidence. (2025). PubMed . https://pubmed.ncbi.nlm.nih.gov/

What are your thoughts on Cleveland Clinic's assessment of fish oil supplements?If I want to go on your sleep protocol, should I order all of the supplements or choose one?Do you still recommend individual assessments to determine natural treatments for anxiety and depression?Is taking Bergamot for cholesterol really effective?

The new vaccine schedule recommendationsMy urologist is giving me grief that my vitamin D level is too highWhich nattokinase do you recommend to treat long covid?Is the vitamin K in your bone protocol different from the heart protocol?What about methylated B vitamins for brain vs. heart health?

Technical Tips for Rotator Cuff Repair, Practice Growth & Social Media | Dr. Hussein Saad Youtube:: https://youtu.be/W6BzLHteAz0 On this episode of the Nailed It Ortho Podcast, we sit down with Dr. Hussein Saad, a board-certified orthopedic surgeon and sports medicine specialist, for a conversation that goes beyond the operating room, covering technical pearls for rotator cuff repair, building a successful orthopedic practice, and leveraging social media as a physician. Dr. Saad earned his medical degree from Wayne State University School of Medicine before completing his orthopedic surgery residency at William Beaumont Hospital in Royal Oak, Michigan. He then completed an Orthopedic Sports Medicine Fellowship at the Cleveland Clinic, where his training included caring for professional athletes from the Cleveland Browns, Cleveland Cavaliers, and Cleveland Indians (now Guardians). With a particular interest in shoulder surgery, sports medicine, and arthroscopy, Dr. Saad joins us to break down some of the technical details that can make a difference when performing arthroscopic rotator cuff repair. We discuss surgical decision-making, technical pearls, and strategies he has developed throughout his career. We also step outside the OR to talk about another side of being a modern orthopedic surgeon: growing a practice and developing an effective social media presence. Dr. Saad shares his experience building his orthopedic practice, connecting with patients, and using social media to educate while expanding his reach and personal brand. In this episode, we discuss: Technical pearls for arthroscopic rotator cuff repair Rotator cuff repair strategy and surgical decision-making Tips for improving efficiency and reproducibility in the OR Lessons learned from challenging rotator cuff cases Building and growing a successful orthopedic practice How physicians can use social media to educate patients and grow their reach Developing an authentic physician brand Practical advice for residents, fellows, and young orthopedic surgeons building their careers Whether you're an orthopedic resident, fellow, practicing surgeon, or simply looking to improve your rotator cuff technique and understand the business and branding side of medicine, this episode has something for you.

In this episode, Surendra Khera, MD, MSc, President, Cleveland Clinic Florida Accountable Care Organization; Vice Chief, Primary Care Institute, Florida Market, Cleveland Clinic, discusses how expanding access, redesigning primary care, and embracing AI are improving patient outcomes and clinician well-being. He also shares strategies for addressing digital workload, strengthening value-based care, and preparing primary care for the future.

Cleveland Sirens president Allison Howard joins Ken and Anthony to explain how a year-long community listening tour led to the Sirens name over bringing back the Rockers, and why the team intentionally broke away from Cavs colors and branding to build its own identity. She reveals the franchise topped 10,000 season ticket members and six figures in merchandise sales within hours of the reveal, with a fan fest planned for Saturday at Edgewater Beach. Howard also touches on the business case for investing in women's sports, partnerships with Cleveland Clinic to help players handle online scrutiny, and the road ahead before the Sirens actually take the court in 2028.

The fastest way to stall your growth is to be the most accomplished person in your circle. Peter and Craig are living the opposite this summer. Craig is recording from Aspen and Peter just got back from Baker's Bay, both dropped into rooms where they quickly realized they are a smallest fish in the pond, which is exactly where they want to be. Recorded the week of the sold-out Bulletproof Summit, the conversation starts with a question: why does dentistry attack its own? Post about expanding from ten to twenty operatories in a dental Facebook group and the comments call it a factory and a chop shop. Yet nobody calls the Cleveland Clinic a factory. Peter and Craig dig into where that hostility comes from, and why the bigger danger isn't the keyboard warriors, it's the current you're floating in without knowing it. As Peter admitted last episode, he spent a decade suffering and didn't know it, because everyone around him treated misery as par for the course. The way out is proximity. Leaders in peer groups grow more than twice as fast as comparable companies, and the guys unpack why: mirror neurons, borrowed belief, watching someone run the four minute mile and realizing you can too. They cover how to pick the right group and avoid the prescriptive ones that grind dentists down, why you should only take advice from people living the life you want, a practical tip for tapping the successful patients already in your chair, and why they've always refused to sell a virtual Summit ticket. The breakthrough was never the content. It's the room.